Subject Index

A

***N*-Acetyldopamine**, antitumor activity against murine leukemia, 991
***Achromobacter* L-glutaminase-L-asparaginase**
human pharmacology, toxicology, and activity in acute leukemias, 1019
nonimmunogenic, treatment of L5178Y tumor-bearing BDF_1 mice with, 1127
***Acinetobacter* L-glutaminase-L-asparaginase**
biologic and antineoplastic effects of, 1045
enhanced effect of L-(α*S*,5*S*)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid by, 1109
succinylated, phase I study of, 1025
Aclacinomycin A
clinical study of, 931
electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with, 875
4′-(9-Acridinylamino)methanesulfon-*m*-anisidide (AMSA)
neurologic and cardiac rhythm abnormalities associated with, in man, 2001
phase II study of, in the treatment of metastatic breast cancer, 1961
Actinomycin D
combined with procarbazine and vinblastine in stage III and IV melanoma with or without methanol-extracted residue of bacillus Calmette-Guérin, 197
combined with vinblastine, bleomycin, *cis*-dichlorodiammineplatinum(II), and cyclophosphamide for the treatment of germ-cell tumors, 1675
AD-32
electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with, 875
initial clinical evaluation of, 919
Adriamycin
acute cardiovascular alterations induced by low doses of, in the anesthetized beagle dog, 1771
"Adriamycin flare": a skin reaction resembling extravasation, 2067
alone or combined with DTIC and other agents in the treatment of cancer of the stomach, 411
alterations of lactate dehydrogenase isoenzymes with subacute Adriamycin toxicity, 2057
analogs, structure-activity relationships among, 845
as part of combination therapy for mycosis fungoides, 647
as part of combined modality therapy for mycosis fungoides, 713
cardiomyopathy, failure of carnitine to prevent, 558
cardiotoxicity, a survey of 1273 patients, 827
cardiotoxicity, experimental animal models of, 855
cardiotoxicity in the mouse, quantitative experimental evaluation of, 1877
combined with cyclophosphamide and bacillus Calmette-Guérin in the treatment of advanced ovarian carcinoma, 325
combined with cyclophosphamide and *cis*-dichlorodiammineplatinum(II), phase II study of, in the treatment of adenocarcinoma and large cell carcinoma of the lung, 1589
combined with cyclophosphamide and followed by radiation therapy, patterns of relapse in patients with small cell carcinoma of the lung treated with, 359
combined with cyclophosphamide and 5-fluorouracil (CAF) and compared to melphalan alone, triethylenethiophosphoramide and methotrexate, and a fixed rotation of triethylenethiophosphoramide-methotrexate and CAF in the treatment of advanced ovarian cancer: a preliminary report, 297
combined with cyclophosphamide and VP-16-213 (intensive induction therapy) followed by BCNU, vincristine, methotrexate, and procarbazine in the treatment of small cell carcinoma of the lung, 519
combined with cyclophosphamide, hexamethylmelamine, and *cis*-dichlorodiammineplatinum(II) (CHAD), phase II trial of, in the treatment of advanced ovarian carcinoma, 307
combined with cyclophosphamide, hexamethylmelamine, and *cis*-dichlorodiammineplatinum(II) (CHAD regimen) and compared to hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II) (HAD regimen) in the treatment of advanced ovarian cancer, 311
combined with *cis*-dichlorodiammineplatinum(II) and cyclophosphamide (PACe) in the treatment of advanced ovarian carcinoma, 1745
combined with *cis*-dichlorodiammineplatinum(II) and cyclophosphamide (PAC) in the treatment of stage III–IV epithelial ovarian cancer: a preliminary report, 281
combined with *cis*-dichlorodiammineplatinum(II) and 5-fluorouracil in the treatment of advanced bladder cancer, 1573
combined with *cis*-dichlorodiammineplatinum(II), cyclophosphamide, CCNU, and vincristine in the treatment of non-small cell lung carcinoma: a preliminary report, 29
combined with 5-fluorouracil and cyclophosphamide (CAF), phase II study of alternating cytoreductive and cycle-active (CAMELEON) combination chemotherapy for metastatic breast cancer, 2077

combined with 5-fluorouracil and mitomycin C (FAM) in the treatment of metastatic pancreatic and gastric adenocarcinomas, 2049
combined with 5-fluorouracil, hexamethylmelamine, and *cis*-dichlorodiammineplatinum(II) for alkylator-resistant ovarian carcinoma, 301
combined with mitomycin C and cyclophosphamide in the treatment of advanced adenocarcinoma and large cell carcinoma of the lung, 1983
combined with vincristine and prednisone, reinduction therapy for adult acute leukemia, 1413
combined with vincristine and procarbazine (VAP), alternating with high-dose cyclophosphamide, methotrexate, and CCNU (CMC) (followed by VP-16-213 and ifosfamide) in the treatment of small cell lung cancer, 163
comparison of a 5-week schedule with a 3-week schedule in the treatment of breast cancer, 121
and cyclophosphamide, phase II study of, in the treatment of metastatic prostatic carcinoma, 999
and daunorubicin in cancer treatment: an analysis of their roles and limitations, 809
effects of systemically administered, with local hyperthermia on primary tumor and lung metastases, 1279
electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with, 875
experimental skin necrosis produced by, 529
given with cyclophosphamide after *cis*-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy: sequential combination chemotherapy and surgery for disseminated testicular cancer, 1681
hexamethylmelamine in ovarian cancer resistant to, 1375
intrahepatic arterial, combined with 5-fluorouracil and whole-liver irradiation in the treatment of hepatocellular cancer, 1885
pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and Adriamycin, 861
phase II–III studies of, in the treatment of advanced gastric cancer, 1863, 1871
phase II trial of, in carcinoma of the bilharzial bladder, 227
phase II trial of, in the treatment of advanced or recurrent endometrial carcinoma, 21
plus 5-fluorouracil, levamisole, and irradiation, phase II study in carcinoma of the bladder, 183
rational effective medical treatment of skin ulcers due to, 2101
a rationale for ip therapy with, in murine ovarian cancer, 269
and rubidazone, randomized phase II trial of, in women with advanced breast cancer, 1701
skin necrosis, amelioration of, by use of Adriamycin dilution and various drugs, 1003
sorbent removal of, in vitro and in vivo, 1787
systemic allergic reaction to, 150
used with vinblastine, bleomycin, and *cis*-dichlorodiammineplatinum(II) as induction therapy for metastatic nonseminomatous testicular cancer and followed by maintenance chemotherapy or radiotherapy, 1669
1-year followup of cardiac status after, 1809
Adriamycin-DNA complex, clinical studies with: a review, 895
"Adriamycin flare" *see* Adverse effects, man
Adverse effects, animals
acute cardiovascular alterations induced by low doses of Adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog, 1771
amelioration of Adriamycin skin necrosis, by use of Adriamycin dilution and various drugs, 1003
cardiotoxicity of mitomycin C, 555
comparative assessment of neurotoxicity following repeated administration of vinca alkaloids, 35
experimental animal models of Adriamycin cardiotoxicity, 855
interval-force relationship: a technique for evaluating the cardiac toxicity of anthracycline analogs, 869
platinate toxicity: past, present, and prospects, 1475
quantitative experimental evaluation of Adriamycin cardiotoxicity in the mouse, 1877
reduction of renal toxicity of *cis*-dichlorodiammineplatinum(II) by probenecid, 781
skin necrosis produced by Adriamycin: an animal model of Adriamycin ulceration, 529
Adverse effects, man
Adriamycin cardiotoxicity: a survey of 1273 patients, 827
"Adriamycin flare": a skin reaction resembling extravasation, 2067
anaphylactic reaction to high-dose methotrexate, 797
cardiotoxicity of mitomycin C, 555
CCNU nephrotoxicity following sustained remission in oat cell carcinoma, 226
contracture formation secondary to bleomycin, 552
controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results, 501
dermatitis, new side effect of the hypoxic cell sensitizer, misonidazole, 123
estrogen hypercalcemia associated with tamoxifen administration, 2124
failure of carnitine to prevent Adriamycin cardiomyopathy, 558
hypersensitivity reactions to iv melphalan during treatment of multiple myeloma, 399
long-term *cis*-dichlorodiammineplatinum(II) combined with vinblastine and bleomycin: possible association with severe coronary artery disease, 551
nephrotoxicity of *cis*-dichlorodiammineplatinum(II), 1523
nephrotoxic potential of cephalosporin-aminoglycoside combination, 2115
neurologic and cardiac rhythm abnormalities associated with 4′-(9-acridinylamino)methanesulfon-*m*-anisidide (AMSA), 2001
nitrosourea-associated pulmonary fibrosis, 2128
ocular assessment of patients treated with tamoxifen for breast cancer, 1833

ophthalmopathy after neck irradiation therapy for Hodgkin's disease, 1393
pulmonary hyaline membrane disease occurring in the course of VM-26 therapy, 2093
radiation recall associated with VP-16-213, 224
Raynaud's phenomenon, 225
reversible renal dysfunction due to 5-azacytidine, 806
skin ulcers due to Adriamycin, rational effective medical treatment of, 2101
successful re-treatment with *cis*-dichlorodiammineplatinum(II) after apparent allergic reactions, 219
systemic allergic reaction to Adriamycin, 150
tetany: a complication of *cis*-dichlorodiammineplatinum(II) therapy, 547
toxic effects of *cis*-dichlorodiammineplatinum(II), 1527
1-year followup of cardiac status after Adriamycin therapy, 1809

1-Alkyl carbamoyl derivatives of 5-fluorouracil, administered orally, antineoplastic effect of, on sc implanted Lewis lung carcinoma and B16 melanoma, 1895

Amino acids
derivative of, A-748, evaluated in rat ascites hepatomas, 223
lessons from the study of induced alterations in, in patients with cancer, 1013
manipulations of, in cancer treatment, 1137
metabolism, changes in, caused by 6-azauridine triacetate, relevance to cancer treatment, 1041
possibilities for biochemically rational chemotherapy for some malignancies with depleting enzymes and antimetabolites of specific, 1009
Proceedings of the Workshop on Amino Acid Imbalance in the Treatment of Cancer, 1009–1138
specific, in vitro system for detection of antimetabolites of, 1133

Aminoanthraquinones, antitumor activity of, in animal tumors, 425

L-(αS,5S)-α-Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, enhanced effect of, by *Acinetobacter* L-glutaminase-L-asparaginase, 1109

Aminoglycoside-cephalosporin combination, nephrotoxic potential of, 2115

2-Amino-1,3,4-thiadiazole, pharmacokinetic model for, in mouse, dog, and monkey, 1939

Amphotericin B, effects in tissue culture cell lines with potential relevance to clinical studies in mycosis fungoides, 643

AMSA *see* 4′-(9-Acridinylamino)methanesulfon-*m*-anisidide

Anal cancer *see* Cancer, anal

A-748, new antitumor amino acid derivative, evaluated in rat ascites hepatomas, 223

Anguidine
phase I evaluation of a weekly schedule of, 2015
phase I study of, administered weekly for advanced malignancies, 1993
phase II study of, in the treatment of advanced breast cancer, 789

Anthracyclines (*see also* specific drugs), Proceedings of the NCI-EORTC Symposium on New Drugs in Cancer Therapy, 807–936

Antibiotics, oral nonabsorbable, used alone or in combination with protected environment in neutropenic patients, 363

Antithymocyte globulin, in the management of cutaneous T-cell lymphoma, 675

L-Asparaginase, sequential treatment with methotrexate, phase II study of, in advanced refractory breast cancer, 77

L-Aspartic acid, analogs of, in chemotherapy for cancer, 1095

ASTA D-7093 *see* Mesnum

AT-125, antitumor antibiotic, therapy for mouse tumors and human tumor xenografts with, 473

Autologous stem cell reconstitution, role of, in intensive therapy for resistant neoplasms, 461

5-Azacytidine
plus β-2′-deoxythioguanosine in the treatment of refractory adult acute leukemia, 209
and pyrazofurin, antitumor activity of, against murine P388 and L1210 leukemias and colon carcinoma 26, 1857
reversible renal dysfunction due to, 806

Azaserine
antitumor effects of, 1031
diazo analog of L-glutamine with clinical antitumor activity, 1033

6-Azauridine triacetate, changes in amino acid metabolism caused by, relevance to cancer treatment, 1041

Azotomycin, diazo analog of L-glutamine with clinical antitumor activity, 1033

B

Bacillus Calmette-Guérin (*see also* Methanol-extracted residue of bacillus Calmette-Guérin), combined with Adriamycin and cyclophosphamide in the treatment of advanced ovarian carcinoma, 325

BCNU
alone and combined with VM-26, treatment of grade III and IV astrocytomas following surgery and radiation therapy, 1707
as a cause of pulmonary fibrosis, 2128
combined with chlorozotocin, host resistance to tumor after cure of advanced LSA lymphoma by treatment with, 1409
combined with prednisone and cyclophosphamide, treatment of multiple myeloma resistant to melphalan, 1265
escalating schedules of DTIC with CCNU, vincristine, and, for melanoma, 1989
high-dose, with autologous bone marrow infusion: preliminary observations, 1257
topical, treatment of mycosis fungoides with, 623
used in various combinations in the treatment of human lymphoma cells, 373
used with vincristine, methotrexate, and procarbazine after intensive induction therapy (cyclophosphamide, VP-16-213, and Adriamycin) for small cell carcinoma of the lung, 519

Bilharzial bladder cancer *see* Cancer, bladder

BisalkylAAD *see* 1,4-Bis{2-[(2-hydroxyethyl)amino]ethylamino}-9,10-anthracenedione

1,4-Bis{2-[(2-hydroxyethyl)amino]ethylamino}-9,10-anthracenedione (bisalkylAAD), antitumor activity of, in animal tumors, 425

Bladder cancer *see* Cancer, bladder

Bleomycin
- as part of combination therapy for mycosis fungoides, 647
- as part of combined modality therapy for mycosis fungoides, 713
- combined with CCNU and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy, 151
- combined with cyclophosphamide and vincristine and followed by radiotherapy and cyclophosphamide, methotrexate, and bleomycin in the treatment of advanced head and neck cancer, 351
- combined with *cis*-dichlorodiammineplatinum(II) and vinblastine in the treatment of disseminated testicular cancer, 1659, 1663
- combined with *cis*-dichlorodiammineplatinum(II), cyclophosphamide, actinomycin D, and vinblastine for the treatment of germ-cell tumors, 1675
- combined with *cis*-dichlorodiammineplatinum(II), methotrexate, and vincristine in the treatment of head and neck cancer, 1735
- combined with methotrexate and *cis*-dichlorodiammineplatinum(II) in the treatment of advanced cervical cancer, 1005
- combined with methotrexate and high-dose *cis*-dichlorodiammineplatinum(II) in the treatment of advanced epidermoid cancer of the head and neck, 489
- combined with vincristine and methotrexate in the treatment of advanced head and neck cancers, 1997
- combined with vincristine and mitomycin C, intermittent pelvic infusion with, in the treatment of advanced recurrent carcinoma of the cervix, 1379
- contracture formation secondary to, 552
- effects of systemically administered, with local hyperthermia on primary tumor and lung metastases, 1279
- limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of, 211
- long-term,combined with *cis*-dichlorodiammineplatinum(II) and vinblastine: possible association with severe coronary artery disease, 551
- pharmacokinetics of, in the beagle dog, 1821
- plus *cis*-dichlorodiammineplatinum(II) and vinblastine remission-induction therapy followed by cyclophosphamide and Adriamycin: sequential combination chemotherapy and surgery for disseminated testicular cancer, 1681
- used with vinblastine, Adriamycin, and *cis*-dichlorodiammineplatinum(II) as induction therapy for metastatic nonseminomatous testicular cancer and followed by maintenance chemotherapy or radiotherapy, 1669

B16 melanoma *see* Tumor systems, animals

Bone marrow infusion, autologous, high-dose BCNU therapy with: preliminary observations, 1257

Bone scans, role of, in operable breast cancer: an opposing viewpoint, 1241

Brain cancer *see* Cancer, brain

Breast cancer *see* Cancer, breast

Bronchogenic carcinoma *see* Cancer, lung

Bruceantin
- initial clinical studies with, in the treatment of advanced solid tumors, 1843
- phase I study of, in the treatment of advanced solid tumors or hematologic neoplasms, 1929

C

CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil), phase II study of alternating cytoreductive (CAF) and cycle-active (CAMELEON) combination chemotherapy for metastatic breast cancer, 2077

CAMELEON (cytosine arabinoside, methotrexate, leucovorin, and vincristine), phase II study of alternating cytoreductive (CAF) and cycle-active (CAMELEON) combination chemotherapy for metastatic breast cancer, 2077

Cancer *see also* Leukemia
- anal, radiation therapy, 5-fluorouracil, and mitomycin C in the treatment of, 395
- astrocytomas, treatment of grade III and IV, with BCNU alone and in combination with VM-26 following surgery and radiation therapy, 1707
- bladder
  - advanced, *cis*-dichlorodiammineplatinum(II), Adriamycin, and 5-fluorouracil in the treatment of, 1573
  - advanced, new regimen of combination chemotherapy (cyclophosphamide, hydroxyurea, vinblastine, and vincristine) for, 1427
  - bilharzial, phase II trial of Adriamycin in the treatment of, 227
  - bilharzial, phase II trial of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1577
  - *cis*-dichlorodiammineplatinum(II) in the treatment of, 1579
  - phase II study of Adriamycin, 5-fluorouracil, levamisole, and irradiation in the treatment of, 183
  - renal excretion kinetics of high-dose *cis*-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis, 13
  - urinary, phase II evaluation of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1557
- brain
  - cerebral, primary malignant, combination chemotherapy [including Adriamycin, methotrexate, cyclophosphamide, CCNU, and *cis*-dichlorodiammineplatinum(II)] for extracranial metastases of, 1417
  - glioma, VM-26 as a second drug in the treatment of, 511
  - nonresponsiveness of, to VM-26 therapy in children, 155
- breast
  - Adriamycin: comparison of a 5-week schedule with a 3-week schedule in the treatment of, 121

advanced, acute leukemia as a complication of long-term treatment of, 177
advanced, high-dose methotrexate in the treatment of, 757
advanced, phase II evaluation of hexamethylmelamine in the treatment of, 1359
advanced, phase II study of anguidine in, 789
advanced, phase II study of hexamethylmelamine alone and combined with mitomycin C and vincristine in the treatment of, 2053
advanced, randomized phase II study of rubidazone and Adriamycin in women with, 1701
advanced refractory, phase II study with sequential L-asparaginase and methotrexate in the treatment of, 77
advanced, therapeutic effect of tamoxifen alone or combined with medroxyprogesterone acetate in postmenopausal women with, 171
association between steroid hormone receptor status and disease-free interval in, 1271
effect of mithramycin on widespread painful bone metastases in, 1835
male, hormonal therapy with tamoxifen, 539
metastatic, ifosfamide versus cyclophosphamide in combination drug therapy for, 115
metastatic, phase II study of 4′-(9-acridinylamino)methanesulfon-*m*-anisidide (AMSA) in the treatment of, 1961
metastatic, phase II study of alternating cytoreductive (CAF) and cycle-active (CAMELEON) combination chemotherapy in the treatment of, 2077
metastatic, rubidazone in the treatment of, 135
ocular assessment of patients treated with tamoxifen for, 1833
operable, role of routine bone scans in: an opposing viewpoint, 1241
phase II study of maytansine in the treatment of, 507
a preliminary evaluation of the effect of polyestradiol phosphate on, 1803
refractory metastatic, phase II study of ICRF-159 in the treatment of, 111
refractory, phase I–II study of hexamethylmelamine plus dibromodulcitol in the treatment of, 141
role of plasma carcinoembryonic antigen in evaluating patients with, treated with adjuvant chemotherapy, 1303
tamoxifen-induced tumor stimulation and withdrawal response, 1839
carcinoid, metastatic, 5-fluorouracil and streptozotocin in the treatment of, 795
central nervous system, phase II evaluation of thio-TEPA in the treatment of, 1419
cervical
advanced, methotrexate, bleomycin, and *cis*-dichlorodiammineplatinum(II) in the treatment of, 1005
advanced recurrent, intermittent pelvic infusion with vincristine, bleomycin, and mitomycin C in the treatment of, 1379
advanced squamous cell carcinoma, phase II trial of VP-16-213 in the treatment of, 2089
squamous cell, phase II trial of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1549
colorectal
advanced, phase II evaluation of vindesine in the treatment of, 2097
advanced, phase II study of pyrazofurin in the treatment of, 139
advanced, phase I study of thymidine plus 5-fluorouracil infusions in the treatment of, 1
phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and β-2′-deoxythioguanosine in previously treated patients with, 1355
phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in the treatment of, 215
endometrial, advanced or recurrent, phase II trial of Adriamycin in the treatment of, 21
esophageal, phase II study of vindesine in the treatment of, 2019
gastric
Adriamycin used alone or combined with DTIC and other agents in the treatment of, 411
advanced, 5-fluorouracil in the treatment of: a randomized comparison of two routes of delivery, 1979
advanced, phase II–III chemotherapy studies (Adriamycin alone, FAMe, or FMC) in, 1871
advanced, phase II–III chemotherapy studies in, 1863
fetal sulfoglycoprotein antigen and the treatment of, 2121
metastatic, 5-fluorouracil, Adriamycin, and mitomycin C (FAM) in the treatment of, 2049
gastrointestinal, possibilities for a role of L-glutamine and L-asparagine antagonists in the treatment of, 1039
germ-cell
five-drug chemotherapy for [cyclophosphamide, actinomycin D, vinblastine, bleomycin, and *cis*-dichlorodiammineplatinum(II)], 1675
phase II trial of vindesine in the treatment of, 1399
head and neck
advanced, combined radiotherapy and multidrug chemotherapy (cyclophosphamide, vincristine, and bleomycin [during radiotherapy] and cyclophosphamide, methotrexate, and bleomycin [after radiotherapy] in the treatment of, 351
advanced, *cis*-dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of, 1533
advanced epidermoid, methotrexate, bleomycin, and high-dose *cis*-dichlorodiammineplatinum(II) in the treatment of, 489
advanced, phase II evaluation of dianhydrogalactitol in the treatment of, 2081
advanced, phase II evaluation of maytansine in the treatment of, 2061
advanced, phase II trial of pyrazofurin in the treatment of, 2047
advanced, vincristine combined with bleomycin and methotrexate in the treatment of, 1997
cis-dichlorodiammineplatinum(II), methotrexate, bleomycin, and vincristine in the treatment of, 1735
new polychemotherapy (cyclophosphamide, hydrox-

yurea, vinblastine, and vincristine) regimen for: a pilot study, 805
squamous cell, combination chemotherapy pilot studies in, 158
squamous cell, levamisole in the treatment of, 983
hepatic
intrahepatic arterial Adriamycin and 5-fluorouracil combined with whole-liver irradiation in the treatment of, 1885
primary, isotopic immunoglobulin in an integrated multimodal treatment program for: a case report, 131
histiocytosis X, prednisolone, methotrexate, and 6-mercaptopurine in the treatment of, 2125
Hodgkin's disease
opthalmopathy after neck irradiation for, 1393
stage IVB, phase II study of *cis*-dichlorodiammineplatinum(II) in, 763
islet cell, 5-fluorouracil and streptozotocin in the treatment of, 795
lung
adenocarcinoma and large cell carcinoma, phase II study of cyclophosphamide, Adriamycin, and *cis*-dichlorodiammineplatinum(II) by infusion in the treatment of, 1589
advanced adenocarcinoma and large cell, combination chemotherapy with mitomycin C, Adriamycin, and cyclophosphamide in the treatment of, 1983
advanced, cytokinetic chemotherapy design (methotrexate and cyclophosphamide) in the treatment of, 767
advanced, phase II evaluation of chlorozotocin in the treatment of, 2105
non-oat cell, *cis*-dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of, 391
nonresectable, six-drug combination chemotherapy (CCNU, cyclophosphamide, Adriamycin, procarbazine, hexamethylmelamine, and methotrexate) for, 1351
non-small cell, *cis*-dichlorodiammineplatinum(II), Adriamycin, cyclophosphamide, CCNU, and vincristine in the treatment of: a preliminary report, 29
non-small cell, *cis*-dichlorodiammineplatinum(II) in the treatment of, 1585
non-small cell, phase II evaluation of vindesine in the treatment of, 1343
non-small cell, phase II study of high-dose *cis*-dichlorodiammineplatinum(II) in the treatment of, 2107
non-small cell, phase II trial of chlorozotocin in the treatment of, 549
oat cell, CCNU nephrotoxicity following sustained remission in, 226
small cell anaplastic, long-term survivorship in, 1347
small cell anaplastic, phase II study of *cis*-dichlorodiammineplatinum(II) in the treatment of, 543
small cell, cyclic alternating combination chemotherapy (CMC [high-dose cyclophosphamide, methotrexate, and CCNU] and VAP [vincristine, Adriamycin, and procarbazine], followed by VP-16-213 and ifosfamide) in the treatment of, 163
small cell, *cis*-dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for, 1593
small cell, intensive induction therapy (cyclophosphamide, Adriamycin, and VP-16-213) followed by BCNU, vincristine, methotrexate, and procarbazine for, 519
small cell, interaction of thoracic irradiation and chemotherapy on local control and survival in, 1251
small cell, patterns of relapse in patients treated with Adriamycin-cyclophosphamide and radiation therapy, 359
small cell, phase II trial of *cis*-dichlorodiammineplatinum(II) in the treatment of: preliminary results, 1599
small cell, VM-26 in the treatment of, 2011
small cell, VP-16-213 and cyclophosphamide in the treatment of: a long-term followup report, 2130
small cell, VP-16-213 and VM-26 in the treatment of, 1231
lymphoma
advanced malignant, phase II trial of *cis*-dichlorodiammineplatinum(II) in the treatment of: preliminary results, 1599
cutaneous T-cell, antithymocyte globulin in the management of, 675
cutaneous T-cell, blood and lymph node T lymphocytes in, evaluation by light microscopy, 571
cutaneous T-cell, combined modality therapy with electron-beam radiation therapy and systemic combination chemotherapy for, 713
cutaneous T-cell, cytogenetic abnormalities in patients with, 575
cutaneous T-cell, pathology of, 719
cutaneous T-cell, radiation therapy in the management of, 625
cutaneous T-cell, staging and classification of, 725
cutaneous T-cell, ultrastructural appearance of, in skin, lymph nodes, and peripheral blood, 565
immunoregulatory T-cell, current concepts in, 607
malignant, phase II trial of vindesine in the treatment of, 793
non-Hodgkin's, phase II trial of pyrazofurin, alone and in combination with trifluorothymidine in the treatment of, 1423
non-Hodgkin's, VP-16-213 and VM-26 in the treatment of, 1231
phase II evaluation of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1605
vincristine effect on methotrexate cerebrospinal fluid concentration in a patient with, 143
VM-26 in the treatment of, 7
melanoma
advanced malignant, phase II study of high-dose methotrexate in the treatment of, 147
disseminated, combined DTIC and *cis*-dichlorodiammineplatinum(II) in the treatment of, 493
disseminated malignant, *cis*-dichlorodiammineplatinum(II) alone and combined with DTIC in the treatment of, 2005
DTIC and combination therapy for: escalating schedules of DTIC with BCNU, CCNU, and vincristine, 1989

malignant, chemoimmunotherapy (DTIC and *Corynebacterium parvum*) as adjuvant treatment in malignant melanoma, 1739
malignant, *cis*-dichlorodiammineplatinum(II) and DTIC in the treatment of, 2009
malignant, high-dose methotrexate in the treatment of, 1405
malignant, phase I–II study of piperazinedione in adults with, 939
malignant, phase II trial of piperazinedione in the treatment of, 1367
metastatic, combination chemotherapy with CCNU, bleomycin, and vincristine in patients resistant to DTIC therapy, 151
metastatic malignant, phase II trial of dianhydrogalactitol in the treatment of, 525
phase II study of maytansine in the treatment of, 507
regionally confined, regression of, with intra-arterial *cis*-dichlorodiammineplatinum(II), 555
stage III and IV, procarbazine combined with vinblastine and actinomycin D with or without methanol-extracted residue of bacillus Calmette-Guérin in the treatment of, 197
multiple myeloma
hypersensitivity reactions to iv melphalan during treatment of, 399
phase II trial of pyrazofurin in patients with, refractory to standard cytotoxic therapy, 1403
resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU, 1265
mycosis fungoides
combination chemotherapy for, 647
electron-beam therapy for, 639, 691
epidemiologic observations, 597
experience with lymphography in patients with, 581
exposure to chemicals, physical agents, and biologic agents in, 591
methoxsalen photochemotherapy (psoralen plus ultraviolet light) for, 663
methoxsalen photochemotherapy (psoralen plus ultraviolet light) for: long-term followup study, 669
once weekly total-skin electron-beam therapy for, 7 years' experience, 633
preliminary evaluation of 15 chemotherapeutic agents applied topically in the treatment of, 619
radiation therapy alone or followed by combination chemotherapy for, 655
radiation therapy in the management of, 625
review of various forms of therapy for, 729
Scandinavian trials using various treatment modalities, 709
status report of 376 patients at 4 years, 701
topical BCNU in the treatment of, 623
10-year experience with topical mechlorethamine for: comparison with patients treated by total-skin electron-beam radiation therapy, 681
neuroblastoma
childhood, phase II study of VM-26 in the treatment of, 977
childhood, weekly administration of *cis*-dichlorodiammineplatinum(II) in the treatment of, 497
metastatic, phase II study demonstrating failure of both a five-drug continuous-therapy regimen (prednisone, cyclophosphamide, actinomycin D, vincristine, and daunorubicin) and a two-drug pulse-therapy regimen (cyclophosphamide and vincristine) in the treatment of, 1383
preliminary report on the clinical use of human leukocyte interferon in, 2111
osteosarcoma
age-related pharmacokinetics of high-dose methotrexate in patients with, 405
aggressive resection of pulmonary metastases, 753
childhood, phase II study of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1621
effect of adjuvant high-dose methotrexate after amputation, 739
ovarian
advanced adenocarcinoma, phase II trial of VP-16-213 in the treatment of, 2089
advanced, Adriamycin combined with cyclophosphamide and bacillus Calmette-Guérin in the treatment of, 325
advanced, CHAD [cyclophosphamide, hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II)] and HAD [hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II)] regimens in the treatment of, 311
advanced, controlled prospective trial of cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) compared to melphalan alone, triethylenethiophosphoramide and methotrexate, and a fixed rotation of triethylenethiophosphoramide-methotrexate and CAF in the treatment of: a preliminary report, 297
advanced, *cis*-dichlorodiammineplatinum(II), Adriamycin, and cyclophosphamide (PACe) or *cis*-dichlorodiammineplatinum(II) alone in the treatment of, 1745
advanced, *cis*-dichlorodiammineplatinum(II) in the treatment of, 1539
advanced, histologic grade in, 255
advanced, phase II study of Leo 1031 (prednimustine) in the treatment of, 421
advanced, phase II trial of cyclophosphamide, hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II) (CHAD) in the treatment of, 307
advanced, role of cytoreductive surgical treatment in the management of, 235
advanced stage III and IV, melphalan, 5-fluorouracil, and methotrexate given in combination or sequentially in the treatment of: a preliminary report, 289
advanced, treatment and immunodiagnosis of: a preliminary report, 265
analysis of various treatment modalities in patients with stages I, II, and asymptomatic III presentations, 249
combination chemotherapy [Adriamycin, 5-fluorouracil, hexamethylmelamine, and *cis*-dichlorodiammineplatinum(II), or 5-fluorouracil, hexamethylmelamine, and *cis*-dichlorodiammineplat-

inum(II)] for alkylator-resistant disease, 301
different chemotherapeutic sensitivities and host factors affecting prognosis in advanced versus minimal residual disease, 241
an optimistic overview, 333
phase II evaluation of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1557
phase II study of high-dose methotrexate with leucovorin rescue in the treatment of, 275
phase II trial of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1549
primary stage III, melphalan plus *Corynebacterium parvum* in the treatment of, 319
resistant to alkylating agents, phase II trial of hexamethylmelamine in the treatment of, 137
resistant to cyclophosphamide and Adriamycin, hexamethylmelamine in the treatment of, 1375
stage III–IV epithelial, *cis*-dichlorodiammineplatinum(II), Adriamycin, and cyclophosphamide (PAC) in the treatment of: a preliminary report, 281
a summary of experience with *cis*-dichlorodiammineplatinum(II) at The Royal Marsden Hospital, 1545

pancreatic
adenocarcinoma, unresectable, cyclophosphamide and 5-fluorouracil in the treatment of, 2119
metastatic, 5-fluorouracil, Adriamycin, and mitomycin C (FAM) in the treatment of, 2049

prostatic
cis-dichlorodiammineplatinum(II) in the treatment of, 1579
metastatic, melphalan in the treatment of: a pilot study, 228
metastatic, phase II study of Adriamycin and cyclophosphamide in the treatment of, 999
phase II evaluation of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1557

renal cell
advanced, phase II study of nafoxidine in the treatment of, 149
advanced, phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, or dianhydrogalactitol in the treatment of, 513
phase II evaluation of chlorozotocin in the treatment of, 1007

retinoblastoma, bilateral, occurrence of testicular metastasis in a child with, 803

sarcoma
advanced soft tissue and bony, *cis*-dichlorodiammineplatinum(II) in the treatment of, 2027
advanced soft tissue and bony, phase II trial of dianhydrogalactitol in the treatment of, 553
Ewing's, subsequent cancer in patients with, 2043
Ewing's, weekly administration of *cis*-dichlorodiammineplatinum(II) in the treatment of, 497
metastatic soft tissue, *cis*-dichlorodiammineplatinum(II) in the treatment of, 2071

Sézary syndrome
exposure to chemicals, physical agents, and biologic agents in, 591
kinetics of Sézary cell production, 659
review of various forms of therapy for, 729
testicular
applications of biologic tumor markers in, 1643
cis-dichlorodiammineplatinum(II) in the treatment of, 1579
disseminated, *cis*-dichlorodiammineplatinum(II), vinblastine, and bleomycin in the treatment of, 1659, 1663
disseminated, sequential combination chemotherapy and surgery for: *cis*-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy followed by cyclophosphamide and Adriamycin, 1681
five-drug combination including *cis*-dichlorodiammineplatinum(II) in the treatment of, 1687
histologic patterns of various germ-cell tumors, 1629
metastatic, in a child with bilateral retinoblastoma, 803
metastatic nonseminomatous: a preliminary report of induction chemotherapy followed by maintenance chemotherapy or radiotherapy, 1669
nonseminomatous germ-cell, role of radiation therapy in the management of, 1653
nonseminomatous, radiotherapy in the management of, 1649
phase II evaluation of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1557
Proceedings of the National Cancer Institute Conference on *cis*-dichlorodiammineplatinum(II) and Testicular Cancer, 1431–1695
renal excretion kinetics of high-dose *cis*-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis, 13
stage II, basis for adjuvant chemotherapy for, 1693
staging procedures and the role of surgery in the treatment of, 1637
urothelial, phase II trials of *cis*-dichlorodiammineplatinum(II) in the treatment of, 1565

Carcinoembryonic antigen
isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer: a case report, 131
role of, in evaluating patients with breast cancer treated with adjuvant chemotherapy, 1303
standardization experiment for the conduct of multiinstitutional clinical trials, 2031

Cardiotoxicity *see* Adverse effects, animals; Adverse effects, man

Carminomycin, American experience with, 899

Carnitine, failure of, to prevent Adriamycin cardiomyopathy, 558

CCNU
combined with bleomycin and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy, 151
combined with *cis*-dichlorodiammineplatinum(II),

Adriamycin, cyclophosphamide, and vincristine in the treatment of non-small cell lung carcinoma: a preliminary report, 29
combined with high-dose cyclophosphamide and methotrexate (CMC), alternating with vincristine, Adriamycin, and procarbazine (VAP) (and followed by VP-16-213 and ifosfamide) in the treatment of small cell lung cancer, 163
effects of, on hematopoiesis in rats, 377
escalating schedules of DTIC with BCNU, vincristine, and, for melanoma, 1989
nephrotoxicity following sustained remission in oat cell carcinoma, 226
Cell culture studies
cutaneous T-cell lymphomas, in vitro growth of, 587
γ-cystathionase in normal and leukemic cells, 1081
L-cyst(e)ine requirements of malignant cells (L1210 leukemia) in culture and progress toward depletion therapy, 1073
high-pressure liquid chromatographic analysis of 3-deazauridine-5′-triphosphate in human lymphoblastoid cells (line CCRF-CEM), 415
human leukemia, biochemical parameters of growth inhibition of, by antitumor anthracycline agents, 821
human lymphoma, combination chemotherapy with BCNU, 373
L1210 leukemia, cytotoxic effects of the lysosomotropic agents DNA-ellipticine, DNA-daunorubicin, and DNA-ellipticine:daunorubicin on, 43
L-threonine deaminase as a possible antitumor agent, 1089
tissue culture, with potential relevance to clinical studies in mycosis fungoides, amphotericin B effects in, 643
tumor therapy by deprivation of L-methionine, using two normal human cell lines, 1069
Central nervous system cancer *see* Cancer, central nervous system
Cephalosporin-aminoglycoside combination, nephrotoxic potential of, 2115
Cerebrospinal fluid, vincristine effect on methotrexate cerebrospinal fluid concentration in a patient with malignant lymphoma, 143
Cervical cancer *see* Cancer, cervical
CHAD [cyclophosphamide, hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum-(II)]
phase II trial of, in the treatment of advanced ovarian carcinoma, 307
in the treatment of advanced ovarian cancer, 311
1-(2-Chloroethyl)-3-[1-(5′-paranitrobenzoyl-2′,3′-isopropylidene)-α-β-D-ribofuranosyl]-1-nitrosourea (RFCNU), a nonimmunosuppressive nitrosourea, stability and preliminary pharmacokinetic studies of, 1335
Chlorozotocin
combined with BCNU, host resistance to tumor after cure of advanced LSA lymphoma by treatment with, 1409
phase II evaluation of, in patients with renal cell carcinoma, 1007
phase II evaluation of, in the treatment of advanced lung carcinoma, 2105
phase I trial of, 17
phase II trial of, in the treatment of non-small cell carcinoma of the lung, 549
Cholesterol, role of, in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes, 1923
CHOP (cyclophosphamide, Adriamycin, vincristine, and prednisone), for mycosis fungoides, 647
Chronotherapy, methods for testing and achieving, 1428
CHVV (cyclophosphamide, hydroxyurea, vinblastine, and vincristine), new regimen for the treatment of advanced bladder cancer, 1427
Cisplatin *see cis*-Dichlorodiammineplatinum(II)
Clinical trials
analysis and interpretation of response rates for anticancer drugs, 1713
the delta and epsilon errors in the assessment of, 1917
two-stage plans for patient accrual in phase II studies, 1721
CMC (high-dose cyclophosphamide, methotrexate, and CCNU), alternating with vincristine, Adriamycin, and procarbazine (VAP) and followed by VP-16-213 and ifosfamide in the treatment of small cell lung cancer, 163
CMP (cyclophosphamide, methotrexate, and prednisone), as part of combined modality therapy for mycosis fungoides, 713
Colon tumor 26 *see* Tumor systems, animals
Colon tumor 38 *see* Tumor systems, animals
Colorectal cancer *see* Cancer, colorectal
Combination chemotherapy (*see also* specific agents and abbreviations), design and evaluation of trials in experimental animal tumor systems, 799
7-Con-*O*-methylnogarol, and other analogs of the anthracycline antibiotic, nogalamycin, treatment of mouse tumors with, 1971
COP (cyclophosphamide, vincristine, and prednisone), plus bleomycin, for mycosis fungoides, 647
Corynebacterium parvum
combined with melphalan in the treatment of primary stage III ovarian cancer, 319
and DTIC, used as chemoimmunotherapy (adjuvant treatment) for malignant melanoma, 1739
Cyclocytidine
evaluation of, in children with advanced acute leukemia and solid tumors, 1331
phase I–II study of, in the treatment of refractory acute childhood leukemia, 1913
Cyclophosphamide
and Adriamycin, phase II study of, in the treatment of metastatic prostatic carcinoma, 999
as part of combination therapy for mycosis fungoides, 647
as part of combined modality therapy for mycosis fungoides, 655, 713
combined with actinomycin D, vinblastine, bleomycin, and *cis*-dichlorodiammineplatinum(II) for the treatment of germ-cell tumors, 1675

combined with Adriamycin and bacillus Calmette-Guérin in the treatment of advanced ovarian carcinoma, 325
combined with Adriamycin and *cis*-dichlorodiammineplatinum(II), phase II study of, in the treatment of adenocarcinoma and large cell carcinoma of the lung, 1589
combined with Adriamycin and 5-fluorouracil (CAF) and compared to melphalan alone, triethylenethiophosphoramide and methotrexate, and a fixed rotation of triethylenethiophosphoramide-methotrexate and CAF in the treatment of advanced ovarian cancer: a preliminary report, 297
combined with Adriamycin and 5-fluorouracil (CAF), phase II study of alternating cytoreductive and cycle-active (CAMELEON) combination chemotherapy for metastatic breast cancer, 2077
combined with Adriamycin and followed by radiation therapy, patterns of relapse in patients with small cell carcinoma of the lung treated with, 359
combined with Adriamycin and VP-16-213 (intensive induction therapy) followed by BCNU, vincristine, methotrexate, and procarbazine in the treatment of small cell carcinoma of the lung, 519
combined with *cis*-dichlorodiammineplatinum(II) and Adriamycin (PACe) in the treatment of advanced ovarian carcinoma, 1745
combined with *cis*-dichlorodiammineplatinum(II) and Adriamycin (PAC) in the treatment of stage III–IV epithelial ovarian cancer: a preliminary report, 281
combined with *cis*-dichlorodiammineplatinum(II), Adriamycin, CCNU, and vincristine in the treatment of non-small cell lung carcinoma: a preliminary report, 29
combined with 5-fluorouracil in the treatment of unresectable pancreatic adenocarcinoma, 2119
combined with hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II) (CHAD regimen) and compared to hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II) (HAD regimen) in the treatment of advanced ovarian cancer, 311
combined with hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II) (CHAD), phase II trial of, in the treatment of advanced ovarian carcinoma, 307
combined with hydroxyurea, vinblastine, and vincristine for advanced bladder cancer, 1427
combined with hydroxyurea, vinblastine, and vincristine for head and neck tumors, 805
combined with mitomycin C and Adriamycin in the treatment of advanced adenocarcinoma and large cell carcinoma of the lung, 1983
combined with prednisone and BCNU or prednisone alone, treatment of multiple myeloma resistant to melphalan, 1265
combined with vincristine and bleomycin and followed by radiotherapy and cyclophosphamide, methotrexate, and bleomycin in the treatment of advanced head and neck cancer, 351
combined with vincristine and prednisone in the treatment of refractory chronic lymphocytic leukemia, 441
combined with VP-16-213 in the treatment of small cell lung cancer: a long-term followup report, 2130
followed by methotrexate in the treatment of advanced lung cancer, cytokinetic chemotherapy design, 767
given with Adriamycin after *cis*-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy: sequential combination chemotherapy and surgery for disseminated testicular cancer, 1681
hexamethylmelamine in ovarian cancer resistant to, 1375
high-dose, combined with methotrexate and CCNU (CMC), alternating with vincristine, Adriamycin, and procarbazine (VAP) (and followed by VP-16-213 and ifosfamide) in the treatment of small cell lung cancer, 163
mesnum used as an antidote against the urotoxicity of, 501
phase II study of, in the treatment of advanced renal cell cancer, 513
plus high-dose methotrexate with leucovorin rescue in the treatment of advanced ovarian adenocarcinoma: a preliminary report, 265
plus platinum compounds, schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with, in the treatment of advanced L1210 leukemia, 449
versus ifosfamide in combination drug therapy for metastatic breast cancer, 115
γ-Cystathionase, in normal and leukemic cells, 1081
L-Cyst(e)ine, requirements of malignant cells and progress toward depletion therapy, 1073
Cytosine arabinoside
and daunorubicin, successful reinduction therapy for acute myelogenous leukemia with, 2123
phase I evaluation of, combined with tetrahydrouridine, 1245
plus 5-fluorodeoxyuridine, infusions in patients with solid tumors: phase I study of, 1371
role of cholesterol in enhancing the antitumor activity of, entrapped in liposomes, 1923

D

Daunorubicin
acute cardiovascular alterations induced by low doses of, in the anesthetized beagle dog, 1771
and Adriamycin in cancer treatment: an analysis of their roles and limitations, 809
analogs, structure-activity relationships among, 845
combined with 5-fluorouracil and methyl-CCNU, phase II study of, in the treatment of colorectal cancer, 215
and cytosine arabinoside, successful reinduction therapy for acute myelogenous leukemia with, 2123
cytotoxic effects of, and its DNA-bound lysosomotropic complex, in L1210 leukemia cells, 43
pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and Adriamycin, 861
reduction of the lethality of, by pretreatment with ICRF-159 in Syrian golden hamsters, 89

Daunorubicin-DNA complex (*see also* DNA-daunorubicin), clinical studies with: a review, 895
DBA/2-SL2 lymphosarcoma *see* Tumor systems, animals
3-Deazauridine-5′-triphosphate, high-pressure liquid chromatographic analysis of, in human cancer cells (line CCRF-CEM), 415
2′-Deoxycoformycin, treatment of acute lymphoblastic leukemia with: clinical and biochemical consequences of adenosine deaminase inhibition, 1949
β-2′-Deoxythioguanosine
combined with methyl-CCNU in previously treated patients with colorectal cancer: a phase II evaluation, 1355
pharmacology and toxicology in cancer patients, 53
plus 5-azacytidine in the treatment of refractory adult acute leukemia, 209
Dermatitis *see* Adverse effects, man
Detorubicin
clinical activity of, 889
electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters, 875
pharmacokinetic, toxicologic, and chemotherapeutic properties of, in mice: a comparative study with daunorubicin and Adriamycin, 861
Dianhydrogalactitol
phase II evaluation of, in the treatment of advanced head and neck carcinoma, 2081
phase II study of, in the treatment of advanced renal cell cancer, 513
phase II trial of, in metastatic malignant melanoma, 525
phase II trial of, in the treatment of advanced soft tissue and bony sarcomas, 553
6-Diazo-5-oxo-norleucine *see* DON (6-diazo-5-oxo-norleucine)
Dibromodulcitol, plus hexamethylmelamine in the treatment of refractory breast carcinoma: a phase I-II study, 141
***cis*-Dichlorodiammineplatinum(II)**
in adult patients with a variety of tumors, 1609
alone and combined with DTIC in the treatment of disseminated malignant melanoma, 2005
alone or combined with Adriamycin and cyclophosphamide (PACe) in the treatment of advanced ovarian carcinoma, 1745
alone or in combination as initial treatment of advanced head and neck cancer, 1533
analogs, antileukemic (L1210) activity and toxicity of, 1503
anticancer activity of, and some relevant chemistry, 1433
antitumor activity of, in animal tumors, 1453
combination chemotherapy and cross-resistance studies with tumors of mice, 1459
combined with Adriamycin and cyclophosphamide (PAC) in the treatment of stage III-IV epithelial ovarian cancer: a preliminary report, 281
combined with Adriamycin and 5-fluorouracil in the treatment of advanced bladder cancer, 1573
combined with Adriamycin, 5-fluorouracil, and hexamethylmelamine or with 5-fluorouracil and hexamethylmelamine for alkylator-resistant ovarian carcinoma, 301
combined with bleomycin, vinblastine, actinomycin D, and cyclophosphamide for the treatment of germ-cell tumors, 1675
combined with cyclophosphamide and Adriamycin, phase II study of, in the treatment of adenocarcinoma and large cell carcinoma of the lung, 1589
combined with cyclophosphamide, hexamethylmelamine, and Adriamycin (CHAD), phase II trial of, in the treatment of advanced ovarian carcinoma, 307
combined with cyclophosphamide, hexamethylmelamine, and Adriamycin (CHAD regimen) and compared to hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II) (HAD regimen) in the treatment of advanced ovarian cancer, 311
combined with Adriamycin, cyclophosphamide, CCNU, and vincristine in the treatment of non-small cell lung carcinoma: a preliminary report, 29
combined with DTIC in the treatment of disseminated melanoma, 493
combined with methotrexate and bleomycin in the treatment of advanced cervical cancer, 1005
combined with methotrexate, bleomycin, and vincristine in the treatment of head and neck cancer, 1735
combined with vinblastine and bleomycin in the treatment of disseminated testicular cancer, 1659, 1663
combined with VP-16-213 in the treatment of small cell carcinoma of the lung: an active induction regimen, 1593
disposition and distribution of platinum following parenteral administration of, to animals, 1485
and DTIC in the treatment of malignant melanoma, 2009
effect of a forced diuresis on the distribution and excretion (via urine and bile) of ^{195m}platinum when given as ^{195m}platinum *cis*-dichlorodiammineplatinum(II), 951
evaluation of, in children with advanced malignant diseases, 1611
and hexamethylmelamine in the treatment of non-oat cell lung cancer, 391
high-dose, combined with methotrexate and bleomycin in the treatment of advanced epidermoid cancer of the head and neck, 489
high-dose, phase II study of, in the treatment of non-small cell lung cancer, 2107
high-dose, renal excretion kinetics of, when administered with hydration and mannitol diuresis in the treatment of testicular or bladder cancer, 13
included in a five-drug combination in the treatment of testicular cancer, 1687
incompatibility of aluminum-containing iv administration equipment with, 2118
intra-arterial, regression of regionally confined melanoma with, 555
long-term, combined with vinblastine and bleomycin: possible association with severe coronary artery disease, 551
mechanism of action of, 1439
mode of DNA binding, 1445

nephrotoxicity of, in man, 1523
an observation on the stability of: a caution regarding its administration, 2117
pharmacokinetics of non-protein-bound platinum species following administration of, 1515
pharmacokinetic study of, in the beagle dog: thermodynamic and kinetic behavior of, in a biologic milieu, 59
phase II evaluation of, in lymphomas, 1605
phase II evaluation of, in the treatment of advanced malignancies of the genitourinary and gynecologic organs, 1557
phase II study of, in childhood osteosarcoma, 1621
phase II study of, in small cell anaplastic bronchogenic carcinoma, 543
phase II study of, in the treatment of bilharzial bladder cancer, 1577
phase II study of, in the treatment of stage IVB Hodgkin's disease, 763
phase II trial of, in advanced malignant lymphoma and small cell lung cancer: preliminary results, 1599
phase II trials of, in the treatment of gynecologic malignancies, 1549
phase II trials of, in the treatment of urothelial cancer, 1565
platinum concentrations in bile and plasma following rapid and 6-hour infusions of, 2023
plus vinblastine and bleomycin as remission-induction therapy followed by cyclophosphamide and Adriamycin: sequential combination chemotherapy and surgery for disseminated testicular cancer, 1681
Proceedings of the National Cancer Institute Conference on *cis*-Platinum and Testicular Cancer, 1431-1695
rationale for development of analogs of, 1493
reduction of the renal toxicity of, by probenecid, 781
species in solution, some quantitative data on, 231
stability in aqueous vehicles, 229
successful re-treatment with, after apparent allergic reactions, 219
tetany: a complication of, 547
toxic effects of, in man, 1527
toxicity: past, present, and prospects, 1475
the trail from an inert electrode to a therapeutic solution, 1431
in the treatment of advanced ovarian cancer, 1539
in the treatment of advanced soft tissue and bony sarcomas, 2027
in the treatment of childhood cancer, with or without Adriamycin and surgery, 1615
in the treatment of genitourinary tumors: experience in 250 patients, 1579
in the treatment of metastatic soft tissue sarcomas, 2071
in the treatment of non-small cell carcinoma of the lung, 1585
in the treatment of ovarian cancer, a summary of experience with, at The Royal Marsden Hospital, 1545
used with vinblastine, Adriamycin, and bleomycin as induction therapy for metastatic nonseminomatous testicular cancer and followed by maintenance chemotherapy or radiotherapy, 1669
weekly administration of, in the treatment of childhood solid tumors, 497
***trans*-Dichlorodiammineplatinum(II)**, mode of DNA binding, 1445
Dichloroethylenediamineplatinum(II) (DEP), mode of DNA binding, 1445
Diglycoaldehyde, phase II evaluation of, in previously treated patients with colorectal cancer, 1355
2,3-Dihydro-1*H*-imidazo[1,2-*b*]pyrazole (IMPY), phase I clinical evaluation of, 1849
3,4-Dihydroxybenzylamine, antitumor activity against murine leukemias, 991
DihydroxybisalkylAAD *see* 1,4-Dihydroxy-5,8-bis{2-[(2-hydroxyethyl)amino]ethylamino}-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis{2-[(2-hydroxyethyl)amino]ethylamino}-9,10-anthracenedione(dihydroxybisalkylAAD), antitumor activity of, in animal tumors, 425
Dimethyltriazenes, mechanism of the antimetastatic action of, 93
DNA-daunorubicin (*see also* Daunorubicin-DNA complex), cytotoxic effects on L1210 leukemia cells, 43
DNA-ellipticine, cytotoxic effects on L1210 leukemia cells, 43
DNA-ellipticine:daunorubicin, cytotoxic effects on L1210 leukemia cells, 43
DON (6-diazo-5-oxo-norleucine)
antitumor effects of, 1031
diazo analog of L-glutamine with clinical antitumor activity, 1033
L-Dopa analogs, melanin precursors as antitumor agents in experimental human and murine leukemia, 991
Dopamine analogs, melanin precursors as antitumor agents in experimental human and murine leukemia, 991
Doxorubicin *see* Adriamycin
DTIC
and combination therapy for melanoma: escalating schedules of DTIC with BCNU, CCNU, and vincristine, 1989
combined with Adriamycin or with Adriamycin and other agents in the treatment of cancer of the stomach, 411
combined with *cis*-dichlorodiammineplatinum(II) in the treatment of disseminated malignant melanoma, 2005
combined with *cis*-dichlorodiammineplatinum(II) in the treatment of disseminated melanoma, 493
and *Corynebacterium parvum*, used as chemoimmunotherapy (adjuvant treatment) for malignant melanoma, 1739
and *cis*-dichlorodiammineplatinum(II) in the treatment of malignant melanoma, 2009

E

Ehrlich ascites carcinoma *see* Tumor systems, animals
Ellipticine, cytotoxic effects of, and its DNA-bound lysosomotropic complex, in L1210 leukemia cells, 43
EMT6 tumor *see* Tumor systems, animals
Endometrial cancer *see* Cancer, endometrial

Endotoxin, and extracts of pregnant mouse uterus, effects of, on the recovery of hemopoiesis after 5-fluorouracil, 1761
4'-Epi-Adriamycin, preliminary phase I study of, 915
Esophageal cancer *see* Cancer, esophageal
Ewing's sarcoma *see* Cancer, sarcoma

F

FAC (5-fluorouracil, Adriamycin, and cyclophosphamide), compared to FAI (5-fluorouracil, Adriamycin, and ifosfamide) for metastatic breast cancer, 115
FAI (5-fluorouracil, Adriamycin, and ifosfamide), compared to FAC (5-fluorouracil, Adriamycin, and cyclophosphamide) for metastatic breast cancer, 115
FAM (5-fluorouracil, Adriamycin, and mitomycin C), in the treatment of metastatic pancreatic and gastric adenocarcinomas, 2049
FAMe (5-fluorouracil, Adriamycin, and methyl-CCNU), phase II–III studies of, in advanced gastric cancer, 1871
Fetal sulfoglycoprotein antigen, and the treatment of gastric cancer, 2121
5-Fluorodeoxyuridine, plus cytosine arabinoside, infusions in patients with solid tumors: phase I study of, 1371
5-Fluorouracil
1-alkyl carbamoyl derivatives of, antineoplastic effect of orally administered, on sc implanted Lewis lung carcinoma and B16 melanoma, 1895
combined with Adriamycin and cyclophosphamide (CAF), phase II study of alternating cytoreductive and cycle-active (CAMELEON) combination chemotherapy for metastatic breast cancer, 2077
combined with Adriamycin and mitomycin C (FAM) in the treatment of metastatic pancreatic and gastric adenocarcinomas, 2049
combined with Adriamycin, hexamethylmelamine, and *cis*-dichlorodiammineplatinum(II) or with hexamethylmelamine and *cis*-dichlorodiammineplatinum(II) for alkylator-resistant ovarian carcinoma, 301
combined with cyclophosphamide and Adriamycin (CAF) and compared to melphalan alone, triethylenethiophosphoramide and methotrexate, and a fixed rotation of triethylenethiophosphoramide-methotrexate and CAF in the treatment of advanced ovarian cancer: a preliminary report, 297
combined with cyclophosphamide in the treatment of unresectable pancreatic adenocarcinoma, 2119
combined with *cis*-dichlorodiammineplatinum(II) and Adriamycin in the treatment of advanced bladder cancer, 1573
combined with intrahepatic arterial Adriamycin and whole-liver irradiation in the treatment of hepatocellular cancer, 1885
combined with methyl-CCNU and daunorubicin, phase II study of, in the treatment of colorectal cancer, 215
combined with mitomycin C and radiation therapy in the treatment of carcinoma of the anus, 395
combined with streptozotocin in the treatment of islet cell carcinoma and metastatic carcinoid tumors, 795
effects of endotoxin and extracts of pregnant mouse uterus on the recovery of hemopoiesis after, 1761
enhancement by thymidine of 5-fluorouracil's inhibition of thymidylate synthetase in human tumors, 1817
given in a combination or sequential regimen with melphalan and methotrexate in the treatment of advanced stage III and IV ovarian cancer: a preliminary report, 289
limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of, 211
plus Adriamycin, levamisole, and irradiation, phase II study in carcinoma of the bladder, 183
plus methyl-CCNU or mitomycin C, phase II–III studies of, in the treatment of advanced gastric cancer, 1863
plus thymidine infusions, phase I study of, in advanced colorectal carcinoma, 1
in the treatment of acute leukemia, 2126
in the treatment of advanced gastric carcinoma: a randomized comparison of two routes of delivery, 1979
FMC (5-fluorouracil, mitomycin C, and cytosine arabinoside), phase II–III studies of, in advanced gastric cancer, 1871
Ftorafur
evidence for toxicologic activity of, independent of conversion to 5-fluorouracil, 1389
pharmacokinetics and metabolism of, in man, 343

G

Gastric cancer *see* Cancer, gastric
Gastrointestinal cancer *see* Cancer, gastrointestinal
Germ-cell cancer *see* Cancer, germ-cell
Glioma *see* Cancer, brain
Glutamine, effects of methionine sulfoximine analogs on the synthesis of, possible chemotherapeutic implications, 1115
Glutathione, effects of methionine sulfoximine analogs on the synthesis of, possible chemotherapeutic implications, 1115
Guanazole, schedule-dependency assessments of, when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia, 449

H

HAD [hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II)], in the treatment of advanced ovarian cancer, 311
Harding-Passey melanoma *see* Tumor systems, animals
Head and neck cancer *see* Cancer, head and neck
Hematopoiesis, effects of CCNU on, in rats, 377
Hepatocellular cancer *see* Cancer, hepatic

Hexamethylmelamine
alone and combined with mitomycin C and vincristine, phase II study of, in the treatment of advanced breast cancer, 2053
combined with Adriamycin and *cis*-dichlorodiammineplatinum(II) (HAD regimen) and compared to cyclophosphamide, Adriamycin, hexamethylmelamine, and *cis*-dichlorodiammineplatinum(II) (CHAD regimen) in the treatment of advanced ovarian cancer, 311
combined with Adriamycin, 5-fluorouracil, and *cis*-dichlorodiammineplatinum(II) or with 5-fluorouracil and *cis*-dichlorodiammineplatinum(II) for alkylator-resistant ovarian carcinoma, 301
combined with cyclophosphamide, Adriamycin, and *cis*-dichlorodiammineplatinum(II) (CHAD), phase II trial of, in the treatment of advanced ovarian carcinoma, 307
and *cis*-dichlorodiammineplatinum(II) in the treatment of non-oat cell lung cancer, 391
in ovarian cancer resistant to cyclophosphamide and Adriamycin, 1375
phase II evaluation of, in advanced breast cancer, 1359
phase II trial of, in ovarian carcinoma resistant to alkylating agents, 137
plus dibromodulcitol in the treatment of refractory breast carcinoma: a phase I–II study, 141
Histiocytosis X *see* Cancer, histiocytosis X
Hodgkin's disease *see* Cancer, Hodgkin's disease
HOP (Adriamycin, vincristine, and prednisone), for mycosis fungoides, 647
Hormones, Abstracts From the First International Congress on Hormones and Cancer, 1143–1225
Hycanthone, phase I study of, 1965
Hydroxyurea
combined with cyclophosphamide, vinblastine, and vincristine for advanced bladder cancer, 1427
combined with vincristine, vinblastine, and cyclophosphamide for head and neck tumors, 805
schedule-dependency assessment of, when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia, 449
Hypercalcemia *see* Adverse effects, man
Hyperthermia
local, effects on primary tumor and lung metastases of systemically administered bleomycin or Adriamycin with, 1279
whole-body, evaluation of, as an adjunct to chemotherapy in murine tumors, 1311

I

ICRF-159 (Razoxane)
limited activity of, in the treatment of advanced acute leukemia, 127
phase II study of, in refractory metastatic breast cancer, 111
treatment of blast cell crisis of chronic myeloid leukemia with, 2085
in the treatment of pediatric solid tumors, 1397
ICRF-187, reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with, in Syrian golden hamsters, 89
Ifosfamide
mesnum used as an antidote against the urotoxicity of, 501
versus cyclophosphamide in combination drug therapy for metastatic breast cancer, 115
and VP-16-213, given after alternating chemotherapy with vincristine, Adriamycin, and procarbazine (VAP) and high-dose cyclophosphamide, methotrexate, and CCNU (CMC) in the treatment of small cell lung cancer, 163
Immunotherapy
antithymocyte globulin in the management of cutaneous T-cell lymphoma, 675
bacillus Calmette-Guérin combined with Adriamycin and cyclophosphamide in the treatment of advanced ovarian carcinoma, 325
Corynebacterium parvum and DTIC, used as chemoimmunotherapy (adjuvant treatment) for malignant melanoma, 1739
Corynebacterium parvum plus melphalan in the treatment of primary stage III ovarian cancer, 319
methanol-extracted residue of bacillus Calmette-Guérin combined with procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma, 197
phase I study of iv administration of methanol-extracted residue of bacillus Calmette-Guérin, 2039
phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guérin by the iv route, 1781
IMPY *see* 2,3-Dihydro-1*H*-imidazo[1,2-*b*]pyrazole
Indolyl-3-alkane α-hydroxylase
biologic and antineoplastic effects of, 1045
an L-tryptophan-depleting enzyme, molecular engineering of, 1123
Interferon, human leukocyte, preliminary report on the clinical use of, in neuroblastoma, 2111
Interval-force relationship, a technique for evaluating the cardiac toxicity of anthracycline analogs, 869
Islet cell cancer *see* Cancer, islet cell
Isotopic immunoglobulin, in an integrated multimodal treatment program for a primary liver cancer: a case report, 131

K

KHT tumor *see* Tumor systems, animals

L

Lactate dehydrogenase isoenzymes, alterations of, with subacute Adriamycin toxicity, 2057
Laminar air flow room, plus oral antibiotics versus oral antibiotics alone in neutropenic patients with acute myeloblastic leukemia, comparative randomized study of, 363
Leo 1031 (prednimustine), phase II study of, in advanced ovarian carcinoma, 421

Leucovorin
rescue, with high-dose methotrexate, phase II study of, in the treatment of ovarian cancer, 275
rescue, with high-dose methotrexate plus cyclophosphamide in the treatment of advanced ovarian adenocarcinoma: a preliminary report, 265
Leukemia
acute
activity of *Achromobacter* L-glutaminase-L-asparaginase in, 1019
adult, combination of 6-mercaptopurine and 6-methylmercaptopurine riboside in the treatment of, 156
adult, continuous central venous access in patients with, 2099
adult, phase I–II study of piperazinedione in, 939
adult refractory, 5-azacytidine plus β-2′-deoxythioguanosine in the treatment of, 209
adult, reinduction therapy for, with Adriamycin, vincristine, and prednisone, 1413
advanced, limited activity of ICRF-159 in the treatment of, 127
childhood, advanced, evaluation of cyclocytidine in, 1331
childhood, phase II study of VM-26 in the treatment of, 977
childhood, phase II study of VP-16-213 in the treatment of, 1755
childhood, refractory, phase I–II study of cyclocytidine in the treatment of, 1913
as a complication of long-term treatment of advanced breast cancer, 177
evaluation of *cis*-dichlorodiammineplatinum(II) in children with, 1611
5-fluorouracil in the treatment of, 2126
lymphoblastic, treatment of, with 2′-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition, 1949
myeloblastic, comparative randomized study of protected environment plus oral antibiotics versus oral antibiotics alone in neutropenic patients with, 363
myelocytic, combination chemotherapy for, during pregnancy: three case reports, 369
myelogenous, successful reinduction therapy for, with cytosine arabinoside and daunorubicin, 2123
nonlymphocytic, treatment of, with neocarzinostatin, 1853
phase II trial of vindesine in, 2063
results of treatment with detorubicin, 889
rubidazone in the treatment of, 925
chronic, lymphocytic refractory, cyclophosphamide, vincristine, and prednisone in the treatment of, 441
chronic myelocytic, use of vinblastine in the terminal phase of, 1385
chronic myeloid, treatment of blast cell crisis of, with ICRF-159, 2085
steroid receptors in, 189
Levamisole
plus Adriamycin, 5-fluorouracil, and irradiation, phase II study in carcinoma of the bladder, 183
in the treatment of squamous cell carcinoma of the head and neck, 983
Levodopa analogs, melanin precursors as antitumor agents in experimental human and murine leukemia, 991
Lewis lung carcinoma *see* Tumor systems, animals
L1210 leukemia *see* Tumor systems, animals
LSA lymphoma *see* Tumor systems, animals
Lung cancer *see* Cancer, lung
L5178Y mouse tumor *see* Tumor systems, animals
Lymphography, experience with, in patients with mycosis fungoides, 581
Lymphoma *see* Cancer, lymphoma
Lysosomotropic agents, cytotoxic effects of, on L1210 leukemia cells, 43

M

MAIQ-1 *see* 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone
Maytansine
phase II evaluation of, in the treatment of advanced head and neck cancer, 2061
phase II study of, in the treatment of breast cancer and melanoma, 507
weekly, phase I study of, given by iv bolus or 24-hour infusion, 1953
MCNU, biologic activity of: a new antitumor nitrosourea, 961
Mechlorethamine
as part of combined modality therapy for mycosis fungoides, 655
differential protection of normal and malignant tissues against the cytotoxic effects of, 971
topical, 10-year experience with, for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy, 681
Medroxyprogesterone acetate, combined with tamoxifen versus tamoxifen alone in the treatment of advanced breast cancer in postmenopausal women, 171
Megace *see* Megestrol acetate
Megestrol acetate, phase II study of, in the treatment of advanced renal cell cancer, 513
Melanoma *see* Cancer, melanoma
Melphalan
alone and with *Corynebacterium parvum* in the treatment of primary stage III ovarian cancer, 319
compared to triethylenethiophosphoramide plus methotrexate, CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil), and a fixed rotation of triethylenethiophosphoramide-methotrexate and CAF in the treatment of advanced ovarian cancer: a preliminary report, 297
given in a combination or sequential regimen with 5-fluorouracil and methotrexate in the treatment of advanced stage III and IV ovarian cancer: a preliminary report, 289
iv, hypersensitivity reactions to, during treatment of multiple myeloma, 399
multiple myeloma resistant to: treatment with cyclophosphamide, prednisone, and BCNU, 1265

in the treatment of metastatic cancer of the prostate: a pilot study, 228
6-Mercaptopurine
combined with 6-methylmercaptopurine riboside in the treatment of adult acute leukemia, 156
combined with prednisolone and methotrexate in the treatment of histiocytosis X, 2125
Mesnum, used as an antidote against the urotoxicity of oxazaphosphorines: preliminary results, 501
Methadone, important clinical pharmacologic considerations in the use of, in cancer patients, 457
Methanol-extracted residue of bacillus Calmette-Guérin (*see also* Bacillus Calmette-Guérin)
combined with procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma, 197
phase I study of iv administration of, 2039
phase I toxicity study of, by the iv route, 1781
Methionine sulfoximine analogs, effects of, on the synthesis of glutamine and glutathione, possible chemotherapeutic implications, 1115
L-Methionine, tumor therapy by deprivation of: rationale and results, 1069
Methotrexate
adjuvant high-dose, effect of, after amputation in patients with osteosarcoma, 739
as part of combined modality therapy for mycosis fungoides, 713
cerebrospinal fluid concentration, effect of vincristine on, in a patient with malignant lymphoma, 143
combined with bleomycin and *cis*-dichlorodiammineplatinum(II) in the treatment of advanced cervical cancer, 1005
combined with bleomycin and high-dose *cis*-dichlorodiammineplatinum(II) in the treatment of advanced epidermoid cancer of the head and neck, 489
combined with *cis*-dichlorodiammineplatinum(II), bleomycin, and vincristine in the treatment of head and neck cancer, 1735
combined with high-dose cyclophosphamide and CCNU (CMC), alternating with vincristine, Adriamycin, and procarbazine (VAP) (and followed by VP-16-213 and ifosfamide) in the treatment of small cell lung cancer, 163
combined with prednisolone and 6-mercaptopurine in the treatment of histiocytosis X, 2125
combined with triethylenethiophosphoramide and compared to melphalan alone, CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil), and a fixed rotation of triethylenethiophosphoramide-methotrexate and CAF in the treatment of advanced ovarian cancer: a preliminary report, 297
combined with vincristine and bleomycin in the treatment of advanced head and neck cancers, 1997
given after cyclophosphamide in the treatment of advanced lung cancer, cytokinetic chemotherapy design, 767
given in a combination or sequential regimen with melphalan and 5-fluorouracil in the treatment of advanced stage III and IV ovarian cancer: a preliminary report, 289
given with cyclophosphamide and bleomycin after radiotherapy and cyclophosphamide, bleomycin, and vincristine in the treatment of advanced head and neck cancer, 351
high-dose, age-related pharmacokinetics of, in patients with osteosarcoma, 405
high-dose, anaphylactic reaction to, 797
high-dose, phase II study of, in the treatment of advanced malignant melanoma, 147
high-dose, with leucovorin rescue in ovarian cancer, a phase II study, 275
high-dose, with leucovorin rescue plus cyclophosphamide in the treatment of advanced ovarian adenocarcinoma: a preliminary report, 265
high-dose, in the treatment of advanced breast cancer, 757
high-dose, in the treatment of malignant melanoma, 1405
sequential treatment with L-asparaginase, phase II study of, in advanced refractory breast cancer, 77
in the treatment of osteosarcoma, combined with aggressive resection of pulmonary metastases, 753
used with procarbazine, BCNU, and vincristine after intensive induction therapy (cyclophosphamide, VP-16-213, and Adriamycin) for small cell carcinoma of the lung, 519
and vincristine, schedule-dependent synergism of, against murine L1210 leukemia, 1889
Methoxsalen photochemotherapy (psoralen plus ultraviolet light)
for mycosis fungoides, 663
for mycosis fungoides: long-term followup study, 669
4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone, schedule-dependency assessments of, when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia, 449
Methyl-CCNU
alterations in the toxicity and antitumor activity of, in mice following pretreatment with either phenobarbital or SKF 525A, 1901
combined with β-2′-deoxythioguanosine in previously treated patients with colorectal cancer: a phase II evaluation, 1355
combined with 5-fluorouracil and daunorubicin, phase II study of, in the treatment of colorectal cancer, 215
plus 5-fluorouracil, phase II–III studies of, in the treatment of advanced gastric cancer, 1863
Methyl-GAG, phase I–II trial of, in advanced malignancies, 1933
6-Methylmercaptopurine riboside, combined with 6-mercaptopurine in the treatment of adult acute leukemia, 156
Methylprednisolone
high-dose, combined with vitamins A and C in rapidly growing Morris 7777 hepatoma in rats, 477
high-dose, normal metyrapone response after 1 month of therapy with, a phase I study, 1327
5-Methyltetrahydrohomofolate, disposition of, in mice, dogs, and monkeys, 201
Metyrapone, normal response to, after 1 month of high-dose methylprednisolone in cancer patients: a phase I study, 1327

Misonidazole, hypoxic cell sensitizer, new side effect of, 123
Mithramycin, effect of, on widespread painful bone metastases in cancer of the breast, 1835
Mitomycin C
cardiotoxicity of, in man and animals, 555
combined with Adriamycin and cyclophosphamide in the treatment of advanced adenocarcinoma and large cell carcinoma of the lung, 1983
combined with 5-fluorouracil and Adriamycin (FAM) in the treatment of metastatic pancreatic and gastric adenocarcinomas, 2049
combined with hexamethylmelamine and vincristine, phase II study of, in the treatment of advanced breast cancer, 2053
combined with radiation therapy and 5-fluorouracil in the treatment of carcinoma of the anus, 395
combined with vincristine and bleomycin, intermittent pelvic infusion with, in the treatment of advanced recurrent carcinoma of the cervix, 1379
plus 5-fluorouracil, phase II–III studies of, in the treatment of advanced gastric cancer, 1863
M5076 mouse ovarian tumor *see* Tumor systems, animals
Morris 7777 hepatoma *see* Tumor systems, animals
Multiple myeloma *see* Cancer, multiple myeloma
Murine ovarian cancer *see* Tumor systems, animals
Mutation rate, a mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate, 1727
Mycosis fungoides (*see also* Cancer, lymphoma; Cancer, mycosis fungoides; Cancer, Sézary syndrome), Proceedings of the Workshop on Cutaneous T-Cell Lymphomas (Mycosis Fungoides and Sézary Syndrome), 561–736

N

Nafoxidine, phase II study of, in the treatment of advanced renal carcinoma, 149
Nakahara-Fukuoka sarcoma *see* Tumor systems, animals
Narcotics
important clinical pharmacologic considerations in the use of methadone in cancer patients, 457
use of opiate analgesics in cancer patients, 341
Neocarzinostatin, in the treatment of acute nonlymphocytic leukemia, 1853
Nephrotoxicity *see* Adverse effects, animals; Adverse effects, man
Neuroblastoma *see* Cancer, neuroblastoma
Neurologic toxicity *see* Adverse effects, animals; Adverse effects, man
Nogalamycin, anthracycline antibiotic, treatment of mouse tumors with 7-con-*O*-methylnogarol and other analogs of, 1971

O

Ocular toxicity *see* Adverse effects, man
Opiate analgesics, use of, in cancer patients, 341
Osteosarcoma *see* Cancer, osteosarcoma
Ovarian cancer *see* Cancer, ovarian
Oxazaphosphorines (*see also* cyclophosphamide and ifosfamide), controlled clinical studies with an antidote against the urotoxicity of: preliminary results, 501

P

PAC [*cis*-dichlorodiammineplatinum(II), Adriamycin, and cyclophosphamide], in the treatment of stage III–IV epithelial ovarian cancer: a preliminary report, 281
PACe [*cis*-dichlorodiammineplatinum(II), Adriamycin, and cyclophosphamide], in the treatment of advanced ovarian carcinoma, 1745
PALA *see N*-(Phosphonacetyl)-L-aspartic acid
Pancreatic cancer *see* Cancer, pancreatic
Peptichemio, clinical evaluation of, in patients with solid tumors, 385
Pharmacokinetics
age-related, of high-dose methotrexate in patients with osteosarcoma, 405
and metabolism of ftorafur in man, 343
of non-protein-bound platinum species following administration of *cis*-dichlorodiammineplatinum(II), 1515
pharmacokinetic model for 2-amino-1,3,4-thiadiazole in mouse, dog, and monkey, 1939
pharmacokinetic study of *cis*-dichlorodiammineplatinum(II) in the beagle dog: thermodynamic and kinetic behavior of *cis*-dichlorodiammineplatinum(II) in a biologic milieu, 59
properties of VP-16-213 and VM-26, active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies, 1231
stability and preliminary pharmacokinetic studies of 1-(2-chloroethyl)-3-[1-(5′-paranitrobenzoyl-2′,3′-isopropylidene)-α,β-D-ribofuranosyl]-1-nitrosourea (RFCNU), a nonimmunosuppressive nitrosourea, 1335
of tallysomycin and bleomycin in the beagle dog, 1821
Phase I studies
of anguidine administered weekly for advanced malignancies, 1993
of bruceantin in advanced solid tumors or hematologic neoplasms, 1929
of chlorozotocin, 17
of cyclocytidine in the treatment of refractory acute childhood leukemia, 1913
of 2,3-dihydro-1*H*-imidazo[1,2-*b*]pyrazole, 1849
early clinical study with quelamycin, 903
of 4′-epi-Adriamycin, 915
of 5-fluorodeoxyuridine plus cytosine arabinoside infusions in patients with solid tumors, 1371
of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast, 141

of hycanthone, 1965
of iv administration of methanol-extracted residue of bacillus Calmette-Guérin, 2039
of methanol-extracted residue of bacillus Calmette-Guérin by the iv route, 1781
of methyl-GAG in advanced malignancies, 1933
of a new form of an oral administration of VP-16-213, 485
normal metyrapone response after 1 month of high-dose methylprednisolone in cancer patients, 1327
of *N*-(phosphonacetyl)-L-aspartic acid (PALA), 1909
of piperazinedione in adults with solid tumors and acute leukemia, 939
of piperazinedione in the treatment of advanced cancer, 73
of streptozotocin, continuous infusion, 2035
of succinylated *Acinetobacter* L-glutaminase-L-asparaginase, 1025
of tetrahydrouridine combined with cytosine arabinoside, 1245
of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma, 1
of weekly maytansine given by iv bolus or 24-hour infusion, 1953
of a weekly schedule of anguidine, 2015

Phase II studies

4′-(9-acridinylamino)methanesulfon-*m*-anisidide (AMSA) in the treatment of metastatic breast cancer, 1961
of Adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma, 999
of Adriamycin, 5-fluorouracil, levamisole, and irradiation in carcinoma of the bladder, 183
of Adriamycin in carcinoma of the bilharzial bladder, 227
of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma, 21
of alternating cytoreductive (CAF) and cycle-active (CAMELEON) combination chemotherapy for metastatic breast cancer, 2077
of anguidine in the treatment of advanced breast cancer, 789
chemotherapy studies in advanced gastric cancer, 1863, 1871
of chlorozotocin in renal cell carcinoma, 1007
of chlorozotocin in the treatment of advanced lung cancer, 2105
of chlorozotocin in the treatment of non-small cell carcinoma of the lung, 549
of cyclocytidine in the treatment of refractory acute childhood leukemia, 1913
of cyclophosphamide, Adriamycin, and *cis*-dichlorodiammineplatinum(II) by infusion in the treatment of adenocarcinoma and large cell carcinoma of the lung, 1589
of cyclophosphamide, hexamethylmelamine, Adriamycin, and *cis*-dichlorodiammineplatinum(II) (CHAD) in the treatment of advanced ovarian carcinoma, 307
demonstrating failure of both a five-drug continuous-therapy regimen (prednisone, cyclophosphamide, actinomycin D, vincristine, and daunorubicin) and a two-drug pulse-therapy regimen (cyclophosphamide and vincristine) in the treatment of metastatic neuroblastoma, 1383
of dianhydrogalactitol in patients with metastatic malignant melanoma, 525
of dianhydrogalactitol in the treatment of advanced head and neck carcinoma, 2081
of dianhydrogalactitol in the treatment of advanced soft tissue and bony sarcomas, 553
of *cis*-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs, 1557
of *cis*-dichlorodiammineplatinum(II) in advanced malignant lymphoma and small cell lung cancer: preliminary results, 1599
of *cis*-dichlorodiammineplatinum(II) in childhood osteosarcoma, 1621
of *cis*-dichlorodiammineplatinum(II) in lymphomas, 1605
of *cis*-dichlorodiammineplatinum(II) in the treatment of bilharzial bladder cancer, 1577
of *cis*-dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies, 1549
of *cis*-dichlorodiammineplatinum(II) in the treatment of small cell anaplastic lung cancer, 543
of *cis*-dichlorodiammineplatinum(II) in the treatment of stage IVB Hodgkin's disease, 763
of *cis*-dichlorodiammineplatinum(II) in the treatment of urothelial cancer, 1565
of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and β-2′-deoxythioguanosine in previously treated patients with colorectal cancer, 1355
of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer, 215
of hexamethylmelamine alone and combined with mitomycin C and vincristine in advanced breast cancer, 2053
of hexamethylmelamine in advanced breast cancer, 1359
of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents, 137
of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast, 141
of high-dose *cis*-dichlorodiammineplatinum(II) in the treatment of non-small cell lung cancer, 2107
of high-dose methotrexate in the treatment of advanced malignant melanoma, 147
of high-dose methotrexate with leucovorin rescue in ovarian cancer, 275
of ICRF-159 in refractory metastatic breast cancer, 111
of Leo 1031 (prednimustine) in advanced ovarian carcinoma, 421
of maytansine in breast cancer and melanoma, 507
of maytansine in patients with advanced head and neck cancer, 2061
of methyl-GAG in advanced malignancies, 1933
of nafoxidine in the treatment of advanced renal carcinoma, 149
of piperazinedione in adults with solid tumors and acute leukemia, 939
of piperazinedione in malignant melanoma, 1367

of pyrazofurin, alone and in combination with trifluorothymidine, in non-Hodgkin's lymphoma, 1423
of pyrazofurin in advanced head and neck cancer, 2047
of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy, 1403
of pyrazofurin in the treatment of advanced colorectal carcinoma, 139
randomized, of rubidazone and Adriamycin in women with advanced breast cancer, 1701
of sequential L-asparaginase and methotrexate in advanced refractory breast cancer, 77
of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, or dianhydrogalactitol in the treatment of advanced renal cell cancer, 513
of thioTEPA in the treatment of central nervous system tumors, 1419
two-stage plans for patient accrual in, 1721
of vindesine in acute leukemia, 2063
of vindesine in patients with germ-cell tumors, 1399
of vindesine in patients with non-small cell carcinoma of the lung, 1343
of vindesine in the treatment of advanced colorectal carcinoma, 2097
of vindesine in the treatment of esophageal carcinoma, 2019
of vindesine in the treatment of malignant lymphoma, 793
of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies, 977
of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary, 2089
of VP-16-213 in the treatment of childhood malignant disease, 1755

Phase III studies, chemotherapy studies in advanced gastric cancer, 1863, 1871

Phenobarbital, alterations in the toxicity and antitumor activity of methyl-CCNU in mice following pretreatment with, 1901

L-Phenylalanine ammonia-lyase, biochemical properties and immunogenicity of: effects on tumor-bearing mice, 1063

***N*-(Phosphonacetyl)-L-aspartic acid (PALA)**
determination of, in dog serum and urine by gas chromatography and selected ion monitoring, 775
enzymatic assay for, 85
mechanisms of sensitivity or resistance of murine tumors to, 1291
phase I study of, 1909

Piperazinedione
phase I–II study of, in adults with solid tumors and acute leukemia, 939
phase II trial of, in malignant melanoma, 1367
phase I trial of, in patients with advanced cancer, 73

Platinum antitumor agents [*see also cis*-Dichlorodiammineplatinum(II); *trans*-dichlorodiammineplatinum-(II)]
analogs of clinical interest, 1509
antileukemic (L1210) activity and toxicity of, 1503
mode of DNA binding of: description of a base sequence-dependent mechanism, 1445
plus cyclophosphamide, schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with, in the treatment of advanced L1210 leukemia, 449
rationale for development of, 1493
structure-activity relationships of, 1499

P388 leukemia *see* Tumor systems, animals

Polyestradiol phosphate, a preliminary evaluation of its effect on breast carcinoma, 1803

Portable infusion pump, limitations of, in ambulatory patients receiving continuous infusions of bleomycin or 5-fluorouracil, 211

Prednimustine *see* Leo 1031

Prednisolone, combined with methotrexate and 6-mercaptopurine in the treatment of histiocytosis X, 2125

Prednisone
as part of combination therapy for mycosis fungoides, 647
as part of combined modality therapy for mycosis fungoides, 655, 713
combined with Adriamycin and vincristine, reinduction therapy for adult acute leukemia, 1413
combined with cyclophosphamide and BCNU or cyclophosphamide alone, treatment of multiple myeloma resistant to melphalan, 1265
combined with cyclophosphamide and vincristine in the treatment of refractory chronic lymphocytic leukemia, 441

Pregnancy, combination chemotherapy for acute myelocytic leukemia during: three case reports, 369

Probenecid, reduction of the renal toxicity of *cis*-dichlorodiammineplatinum(II) by, 781

Procarbazine
as part of combined modality therapy for mycosis fungoides, 655
combined with vinblastine and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of bacillus Calmette-Guérin, 197
combined with vincristine and Adriamycin (VAP), alternating with high-dose cyclophosphamide, methotrexate, and CCNU (CMC) (and followed by VP-16-213 and ifosfamide) in the treatment of small cell lung cancer, 163
used with methotrexate, vincristine, and BCNU after intensive induction therapy (cyclophosphamide, VP-16-213, and Adriamycin) for small cell carcinoma of the lung, 519

Prostatic cancer *see* Cancer, prostatic

***Pseudomonas* L-glutaminase-L-asparaginase,** biologic and antineoplastic effects of, 1045

Psoralen *see* Methoxsalen photochemotherapy

Pulmonary hyaline membrane disease, occurring in the course of VM-26 therapy, 2093

Pulmonary toxicity *see* Adverse effects, man

PUVA *see* Methoxsalen photochemotherapy

PVD (procarbazine, vinblastine, and actinomycin D), with or without methanol-extracted residue of bacillus Calmette-Guérin in stage III and IV melanoma, 197

Pyrazofurin
alone and in combination with trifluorothymidine in the treatment of non-Hodgkin's lymphoma: phase II trial, 1423

and 5-azacytidine, antitumor activity of, against murine P388 and L1210 leukemias and colon carcinoma 26, 1857
phase II study of, in the treatment of advanced colorectal carcinoma, 139
phase II trial of, in patients with multiple myeloma refractory to standard cytotoxic therapy, 1403
phase II trial of, in the treatment of advanced head and neck cancer, 2047
weekly, clinical trial of, 1363

Q

Quelamycin
early clinical trial with, 903
iron toxicity studies of, 909

R

Radiation therapy
and Adriamycin-cyclophosphamide, patterns of relapse in patients with small cell carcinoma of the lung treated with, 359
analysis of various treatment modalities in patients with stages I, II, and asymptomatic III presentations of ovarian cancer, 249
combined with 5-fluorouracil and mitomycin C in the treatment of carcinoma of the anus, 395
combined with multidrug chemotherapy (cyclophosphamide, vincristine, and bleomycin [during radiotherapy] and cyclophosphamide, methotrexate, and bleomycin [after radiotherapy]) in the treatment of advanced head and neck cancer, 351
combined with six-drug combination chemotherapy (CCNU, cyclophosphamide, Adriamycin, procarbazine, hexamethylmelamine, and methotrexate) for nonresectable bronchogenic carcinoma, 1351
electron-beam, alone or followed by combination chemotherapy for mycosis fungoides, 655
electron-beam, and systemic combination chemotherapy, combined modality therapy for cutaneous T-cell lymphomas, 713
electron-beam therapy for mycosis fungoides, 691
isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer: a case report, 131
maintenance, a preliminary report of induction chemotherapy followed by, in the treatment of metastatic nonseminomatous testicular cancer, 1669
in the management of cutaneous T-cell lymphomas, 625
in the management of nonseminomatous testicular carcinoma, 1649
methoxsalen photochemotherapy (psoralen plus ultraviolet light) for mycosis fungoides, 663, 669
to the neck for the treatment of Hodgkin's disease, ophthalmopathy after, 1393
once weekly total-skin electron-beam, for mycosis fungoides: 7 years' experience, 633
plus Adriamycin, 5-fluorouracil, and levamisole, phase II study in carcinoma of the bladder, 183
recall reaction associated with VP-16-213, 224
role of, in the management of nonseminomatous germ-cell tumors of the testis, 1653
and surgery, treatment of grade III and IV astrocytomas with BCNU alone and in combination with VM-26 after, 1707
thoracic interaction of, and chemotherapy on local control and survival in small cell carcinoma of the lung, 1251
total-skin electron-beam therapy for mycosis fungoides, 639
total-skin electron-beam therapy for mycosis fungoides, comparison with patients treated with topical mechlorethamine, 681
whole-liver, combined with intrahepatic arterial Adriamycin and 5-fluorouracil in the treatment of hepatocellular cancer, 1885
Radioimmunoassay, for tallysomycin, 1829
Raynaud's phenomenon *see* Adverse effects, man
Razoxane *see* ICRF-159
Renal cell cancer *see* Cancer, renal cell
Renal excretion kinetics, of high-dose *cis*-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis, 13
Renal toxicity *see* Adverse effects, animals; Adverse effects, man
RFCNU *see* 1-(2-Chloroethyl)-3-[1-(5′-paranitrobenzoyl-2′, 3′-isopropylidene)-α,β-D-ribofuranosyl]-1-nitrosourea
Ridgway osteogenic sarcoma *see* Tumor systems, animals
Rubidazone
acute cardiovascular alterations induced by low doses of, in the anesthetized beagle dog, 1771
and Adriamycin, randomized phase II trial of, in women with advanced breast cancer, 1701
clinical studies with, 925
in the treatment of metastatic breast cancer, 135

S

Sarcoma *see* Cancer, sarcoma
Screening, in vitro, utilization of metabolic activation for, of potential antineoplastic agents, 1795
Sézary syndrome *see* Cancer, lymphoma; Cancer, mycosis fungoides; Cancer, Sézary syndrome
SKF 525A alterations in the toxicity and antitumor activity of methyl-CCNU in mice following pretreatment with, 1901
Skin cancer *see* Cancer, lymphoma; Cancer, mycosis fungoides; Cancer, Sézary syndrome
Skin toxicity *see* Adverse effects, animals; Adverse effects, man
Sodium-2-mercaptoethane sulfonate *see* Mesnum
Statistical methods
analysis and interpretation of response rates for anticancer drugs, 1713

the delta and epsilon errors in the assessment of cancer clinical trials, 1917
two-stage plans for patient accrual in phase II cancer clinical trials, 1721
Stem cell reconstitution, autologous, role of, in intensive therapy for resistant neoplasms, 461
Steroid hormone receptors, association between status of, and disease-free interval in breast cancer, 1271
Steroid receptors, in leukemia, 189
Stomach cancer *see* Cancer, gastric
Streptozotocin
combined with 5-fluorouracil in the treatment of islet cell carcinoma and metastatic carcinoid tumors, 795
continuous infusion, phase I study of, 2035
Subrenal capsule assay, used to rank the sensitivity of humor tumors to *cis*-dichlorodiammineplatinum(II), 1453
Surgical treatment
chemoimmunotherapy (DTIC and *Corynebacterium parvum*) as an adjuvant to, in malignant melanoma, 1739
cytoreductive, role of, in the management of advanced ovarian cancer, 235
and radiation therapy, treatment of grade III and IV astrocytomas with BCNU alone and in combination with VM-26 after, 1707
role of, in the treatment of testicular cancer, 1637
and sequential combination chemotherapy for disseminated testicular cancer: *cis*-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy followed by cyclophosphamide and Adriamycin, 1681
used with Adriamycin and *cis*-dichlorodiammineplatinum(II) in childhood cancer, 1615

T

Tallysomycin
pharmacokinetics of, in the beagle dog, 1821
a radioimmunoassay for, 1829
Tamoxifen
alone or combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women, 171
and estrogen hypercalcemia, 2124
hormonal therapy with, in male breast cancer, 539
induction of tumor stimulation and withdrawal response, 1839
ocular assessment of patients treated with, for breast cancer, 1833
T-cell lymphomas *see* Cancer, lymphoma; Cancer, mycosis fungoides; Cancer, Sézary syndrome
Testicular cancer *see* Cancer, testicular
Tetany *see* Adverse effects, man
Tetrahydrouridine, phase I evaluation of, combined with cytosine arabinoside, 1245
ThioTEPA, phase II evaluation of, in the treatment of central nervous system tumors, 1419
L-Threonine deaminase, as a possible antitumor agent, 1089
Thymidine
enhancement by, of 5-fluorouracil's inhibition of thymidylate synthetase in human tumors, 1817
plus 5-fluorouracil infusions, phase I study of, in advanced colorectal carcinoma, 1
and thymine in biologic fluids during high-dose infusions of thymidine in mice, monkeys, and man, 945
Thymine, and thymidine in biologic fluids during high-dose infusions of thymidine in mice, monkeys, and man, 945
Triethylenethiophosphoramide, combined with methotrexate and compared to melphalan alone, CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil), and a fixed rotation of triethylenethiophosphoramide-methotrexate and CAF in the treatment of advanced ovarian cancer: a preliminary report, 297
Trifluorothymidine, combined with pyrazofurin in the treatment of non-Hodgkin's lymphoma: phase II trial, 1423
TSPA *see* Triethylenethiophosphoramide
Tumor systems, animals
adenocarcinoma 755, biologic activity of MCNU, a new antitumor nitrosourea, 961
B16 melanoma
antineoplastic effect of orally administered 1-alkyl carbamoyl derivatives of 5-fluorouracil on sc implanted, 1895
biologic activity of MCNU, a new antitumor nitrosourea, 961
experimental antitumor activity of aminoanthraquinones in, 425
influence of L-tyrosine phenol-lyase on the growth and metabolism of, 1055
treatment of, with 7-con-*O*-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin, 1971
colon tumor 26
antitumor activity of pyrazofurin in combination with 5-azacytidine against, 1857
combination chemotherapy and cross-resistance studies with *cis*-dichlorodiammineplatinum(II) in, 1459
design and evaluation of combination chemotherapy trials in, 799
experimental antitumor activity of aminoanthraquinones in, 425
colon tumor 38
design and evaluation of combination chemotherapy trials in, 799
evaluation of whole-body hyperthermia as an adjunct to chemotherapy in, 1311
DBA/2-SL2 lymphosarcoma, various forms of therapy in, compared to the Harding-Passey melanoma, 99
Ehrlich ascites carcinoma, enhanced effect of L-(α*S*,5*S*)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid by *Acinetobacter* L-glutaminase-L-asparaginase, 1109
EMT6 tumor, effects of systemically administered bleomycin or Adriamycin with local hyperthermia on primary tumor and lung metastases, 1279
Harding-Passey melanoma, various forms of therapy in, compared to the DBA/2-SL2 lymphosarcoma, 99
KHT tumor, effects of systemically administered bleo-

mycin or Adriamycin with local hyperthermia on primary tumor and lung metastases, 1279
Lewis lung carcinoma
antineoplastic effect of orally administered 1-alkyl carbamoyl derivatives of 5-fluorouracil on sc implanted, 1895
biologic activity of MCNU, a new antitumor nitrosourea, 961
evaluation of whole-body hyperthermia as an adjunct to chemotherapy in, 1311
mechanism of the antimetastatic action of dimethyltriazenes in, 93
L1210 leukemia
advanced, schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of, 449
antileukemic activity of *cis*-dichlorodiammineplatinum(II) analogs in, 1503
antitumor activity of AT-125 in, 473
antitumor activity of L-dopa analogs against, 991
antitumor activity of pyrazofurin in combination with 5-azacytidine against, 1857
biologic activity of MCNU, a new antitumor nitrosourea, 961
combination chemotherapy and cross-resistance studies with *cis*-dichlorodiammineplatinum(II) in, 1459
enhanced effect of L-(α*S*,5*S*)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid by *Acinetobacter* L-glutaminase-L-asparaginase, 1109
experimental antitumor activity of aminoanthraquinones in, 425
schedule-dependent synergism of methotrexate and vincristine against, 1889
treatment of, with 7-con-*O*-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin, 1971
LSA lymphoma, advanced host resistance to tumor after cure of, by treatment with BCNU and chlorozotocin, 1409
L5178Y mouse tumor, treatment of, with nonimmunogenic *Achromobacter* L-glutaminase-L-asparaginase, 1127
mammary adenocarcinoma 16C, evaluation of whole-body hyperthermia as an adjunct to chemotherapy in, 1311
M5076 mouse ovarian tumor, antitumor activity of AT-125 in, 473
Morris 7777 hepatoma, rapidly growing, high-dose methylprednisolone, vitamin A, and vitamin C in rats, 477
murine ovarian cancer, chemotherapy for: a rationale for ip therapy with Adriamycin, 269
Nakahara-Fukuoka sarcoma, biologic activity of MCNU, a new antitumor nitrosourea, 961
P388 leukemia
antitumor activity of AT-125 in, 473
antitumor activity of L-dopa analogs against, 991
antitumor activity of pyrazofurin in combination with 5-azacytidine against, 1857
combination chemotherapy and cross-resistance studies with *cis*-dichlorodiammineplatinum(II) in, 1459
evaluation of whole-body hyperthermia as an adjunct to chemotherapy in, 1311
experimental antitumor activity of aminoanthraquinones in, 425
treatment of, with 7-con-*O*-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin, 1971
rat ascites hepatoma, new antitumor amino acid derivative, A-748, evaluated in, 223
Ridgway osteogenic sarcoma
combination chemotherapy and cross-resistance studies with *cis*-dichlorodiammineplatinum(II) in, 1459
evaluation of whole-body hyperthermia as an adjunct to chemotherapy in, 1311
L-Tyrosine phenol-lyase, influence of, on the growth and metabolism of B16 melanoma, 1055

U

Urothelial cancer *see* Cancer, urothelial
Urotoxicity *see* Adverse effects, man

V

VAB (vincristine, Adriamycin, and bleomycin), as part of combined modality therapy for mycosis fungoides, 713
VAP (vincristine, Adriamycin, and procarbazine), alternating with high-dose cyclophosphamide, methotrexate, and CCNU (CMC) and followed by VP-16-213 and ifosfamide in the treatment of small cell lung cancer, 163
Vinblastine
animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids, 35
combined with bleomycin, *cis*-dichlorodiammineplatinum(II), cyclophosphamide, and actinomycin D for the treatment of germ-cell tumors, 1675
combined with cyclophosphamide, hydroxyurea, and vincristine for advanced bladder cancer, 1427
combined with *cis*-dichlorodiammineplatinum(II) and bleomycin in the treatment of disseminated testicular cancer, 1659, 1663
combined with hydroxyurea, vincristine, and cyclophosphamide for head and neck tumors, 805
combined with procarbazine and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of bacillus Calmette-Guérin, 197
long-term, combined with *cis*-dichlorodiammineplatinum(II) and bleomycin: possible association with severe coronary artery disease, 551
plus *cis*-dichlorodiammineplatinum(II) and bleomycin remission-induction therapy followed by cyclophos-

phamide and Adriamycin: sequential combination chemotherapy and surgery for disseminated testicular cancer, 1681
in the terminal phase of chronic myelocytic leukemia, 1385
used with bleomycin, Adriamycin, and *cis*-dichlorodiammineplatinum(II) as induction therapy for metastatic nonseminomatous testicular cancer and followed by maintenance chemotherapy or radiotherapy, 1669
Vinca alkaloids (*see also* specific agents), animal models for the comparative assessment of neurotoxicity following repeated administration of, 35
Vincristine
animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids, 35
as part of combination therapy for mycosis fungoides, 647
as part of combined modality therapy for mycosis fungoides, 655, 713
combined with Adriamycin and prednisone, reinduction therapy for adult acute leukemia, 1413
combined with Adriamycin and procarbazine (VAP), alternating with high-dose cyclophosphamide, methotrexate, and CCNU (CMC) (and followed by VP-16-213 and ifosfamide) in the treatment of small cell lung cancer, 163
combined with bleomycin and methotrexate in the treatment of advanced head and neck cancers, 1997
combined with bleomycin and mitomycin C, intermittent pelvic infusion with, in the treatment of advanced recurrent carcinoma of the cervix, 1379
combined with CCNU and bleomycin in the treatment of metastatic melanoma in patients resistant to DTIC therapy, 151
combined with cyclophosphamide and bleomycin and followed by radiotherapy and cyclophosphamide, methotrexate, and bleomycin in the treatment of advanced head and neck cancer, 351
combined with cyclophosphamide and prednisone in the treatment of refractory chronic lymphocytic leukemia, 441
combined with cyclophosphamide, hydroxyurea, and vinblastine for advanced bladder cancer, 1427
combined with *cis*-dichlorodiammineplatinum(II), Adriamycin, cyclophosphamide, and CCNU in the treatment of non-small cell lung carcinoma: a preliminary report, 29
combined with *cis*-dichlorodiammineplatinum(II), methotrexate, and bleomycin in the treatment of head and neck cancer, 1735
combined with hexamethylmelamine and mitomycin C, phase II study of, in the treatment of advanced breast cancer, 2053
combined with vinblastine, cyclophosphamide, and hydroxyurea for head and neck tumors, 805
effect on methotrexate cerebrospinal fluid concentration in a patient with malignant lymphoma, 143
escalating schedules of DTIC with BCNU, CCNU, and, for melanoma, 1989
and methotrexate, schedule-dependent synergism of, against murine L1210 leukemia, 1889
used with procarbazine, methotrexate, and BCNU after intensive induction therapy (cyclophosphamide, VP-16-213, and Adriamycin) for small cell carcinoma of the lung, 519
Vindesine
animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids, 35
phase II evaluation of, in the treatment of advanced colorectal carcinoma, 2097
phase II evaluation of, in the treatment of non-small cell carcinoma of the lung, 1343
phase II study of, in patients with germ-cell tumors, 1399
phase II study of, in the treatment of esophageal carcinoma, 2019
phase II trial of, in patients with acute leukemia, 2063
phase II trial of, in the treatment of malignant lymphoma, 793
Vitamin A, combined with vitamin C and high-dose methylprednisolone in rapidly growing Morris 7777 hepatoma in rats, 477
Vitamin C, combined with vitamin A and high-dose methylprednisolone in rapidly growing Morris 7777 hepatoma in rats, 477
VM-26
as a second drug in the treatment of brain gliomas, 511
combined with BCNU, treatment of grade III and IV astrocytomas following surgery and radiation therapy, 1707
nonresponsiveness of brain tumors to, in children, 155
phase II study of, in the treatment of acute leukemia, neuroblastoma, and other refractory childhood malignancies, 977
pulmonary hyaline membrane disease occurring during treatment with, 2093
in the treatment of malignant lymphoma, 7
in the treatment of small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies, 1231
in the treatment of small cell lung carcinoma, 2011
VP-16-213
combined with cyclophosphamide and Adriamycin (intensive induction therapy) followed by BCNU, vincristine, methotrexate, and procarbazine in the treatment of small cell carcinoma of the lung, 519
combined with cyclophosphamide in the treatment of small cell lung cancer: a long-term followup report, 2130
combined with *cis*-dichlorodiammineplatinum(II) in the treatment of small cell carcinoma of the lung: an active induction regimen, 1593
an ifosfamide, given after alternating chemotherapy with vincristine, Adriamycin, and procarbazine (VAP) and high-dose cyclophosphamide, methotrexate, and CCNU (CMC) in the treatment of small cell lung cancer, 163
new form of an oral administration of, phase I trial, 485

phase II evaluation of, in previously treated patients with colorectal cancer, 1355
phase II study of, in the treatment of advanced renal cell cancer, 513
phase II study of, in the treatment of childhood malignant disease, 1755
phase II trial of, in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary, 2089
radiation recall associated with, 224
in the treatment of small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies, 1231

W

WR-2721 (*S*,2-[3-aminopropylamino]ethyl-phosphorothioic acid), differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine, 971

X

Xenografts, human tumor, antitumor activity of AT-125 in, 473

Author Index

A

Abell CW, 1063
Abeloff MD, 519
Abrahm J, 2099
Abrams RA, 461
Abu-Ghazaleh S, 319
Abuchowski A, 1127
Acton EM, 425
Ahmann DL, 1701
Ahmed A, 613
Aisner J, 543
Aitken SC, 1271
Al-Sarraf M, 525, 999, 1609
Alberts DS, 301, 325, 1609
Alcock NW, 2023
Aleman C, 1509
Alexopoulos C, 1545
Allegra JC, 1271
Amer MH, 999
Anderson T, 1687
Andrews T, 307
Ardalan B, 89
Argyropoulos CL, 597, 619
Arlin Z, 2063
Arnold DJ, 150
Arnold ST, 1475
Arseneau JC, 297
Aspegren K, 421
Atkins LM, 449
Au JL, 343
Auclerc G, 889
Auclerc MF, 889

B

Bachur NR, 817
Baffi R, 1739
Bagshaw MA, 625, 691
Bains M, 2019
Baker LH, 899, 1983, 2027
Bakowski MT, 127, 2085
Balcerzak S, 1359
Ballentine R, 13
Band PR, 1839
Bannister SJ, 1515
Barker GH, 1545
Barlock A, 1271, 1687
Barlow JJ, 265
Baron JM, 655
Bartolucci AA, 209, 1367
Barton D, 1593
Bateman JR, 1979, 2119
Batley F, 1735
Bauer M, 513
Baum ES, 1621
Baurain R, 861
Beale FA, 249
Bean HA, 249
Beck M, 1833
Bedikian AY, 411, 1843
Begg CB, 7, 1675
Belfiore G, 1427
Bellet RE, 111
Bellini O, 1877
Belloni C, 1375
Belt RJ, 1515, 1993
Benjamin RS, 77, 135, 411, 555, 757, 925, 939, 2027
Bennett JM, 7, 513
Benvenuto JA, 415
Berenzweig M, 311
Beretta G, 827
Beretta-Piccoli M, 1839
Berger CL, 675
Bernard J, 889
Bernath A, 307
Berry DH, 497
Bertazzoli C, 1877
Bhattacharya M, 265
Bianco A, 158
Bickers JN, 2126
Bier C, 89
Bikel I, 1081
Billings AA, 2049
Bisel HF, 1701
Bitran JD, 2049
Bjornsson S, 2009
Blank N, 581
Blasberg RG, 945
Blessing JA, 21, 319, 1549, 2089
Bleyer WA, 977, 1755
Block JB, 643, 701
Blom J, 1265, 1351
Blum RH, 919, 1929
Blume MR, 493
Blumenschein GR, 77, 115, 135, 539, 757, 789, 1961, 2053
Bodey GP, 77, 115, 156, 385, 411, 507, 555, 757, 789, 939, 1843, 1849, 1961, 2001, 2053
Bogden AE, 473
Bohart RD, 2117
Bolis G, 1375
Bolten BJ, 945

Bonadonna G, 827, 915
Bonfante V, 915
Bonnet J, 1609
Bono VH, Jr, 1431, 1713
Bonomi PD, 137
Borella LD, 1025
Bourut C, 875
Boyes DA, 289, 1379
Bradley TR, 1761
Bradner WT, 1503
Branfman AR, 775
Braverman LE, 1393
Brearley RL, 2085
Brecher ML, 1615
Breed JGS, 869
Britell JC, 2130
Brock N, 501
Broder S, 607
Brodovsky HS, 7, 297
Brodsky I, 1675
Broughton A, 1829
Bruckner HW, 297, 395
Brugarolas A, 909
Buchanan RB, 1745
Buchsbaum HJ, 21
Buehner R, 827
Bukowski RM, 795
Bulkin W, 311
Bull JM, 1539
Bundy B, 2089
Bunn PA, Jr, 163, 561, 565, 571, 575, 587, 591, 659, 713, 725, 1231
Burchenal JH, 1031, 1245, 1493
Burgess MA, 385, 507, 939, 1849
Burkert H, 501
Burroni P, 805
Bush RS, 249
Butts JD, 951
Buzdar AU, 77, 115, 135, 539, 1961, 2053
Byar DP, 701
Byhardt R, 1251

C

Cabanillas F, 507
Cadiz M, 2118
Calabresi P, 1363, 1371
Califano L, 983
Calvo DB, 555
Cameron I, 477
Camitta BM, 1025
Canellos GP, 275, 919, 1681, 1853, 1929
Canetta R, 827
Cangir A, 552, 803, 1397
Caradonna R, 489
Carbone PP, 7, 1355
Carey RW, 215
Carlson M, 1405
Carney DN, 587
Carroll DS, 139, 2097
Carter SK, 935
Casadio M, 1427
Casazza AM, 835, 915
Casper ES, 549, 2023, 2107
Cassidy J, 1539
Cassidy MJ, 1885
Castellani R, 827
Castellino RA, 581
Catalano RR, 111
Catane R, 1033, 1137, 1713, 1721
Cavalli F, 1599, 1669
Cavins J, 2009
Cerna I, 1901
Chabner BA, 147, 739
Chahinian AP, 1953
Chan EYC, 493
Chapman D, 123
Chard RL, Jr, 977, 1755
Chello PL, 1889
Cheng CC, 425
Cheng E, 2047
Chernicoff D, 795
Chevlen E, 227, 1577
Chinen T, 931
Chiuten DF, 7, 1857
Chlebowski RT, 1979, 2119
Cleare MJ, 1499, 1503
Clendenning WE, 619, 701, 719
Cohen C, 395
Cohen MH, 163, 713, 1003
Cohen RJ, 493
Coit R, 1039
Coldman AJ, 1727
Coles DT, 1589
Coltman CA, Jr, 647, 1605, 1609, 2126
Comis RL, 899, 1347
Commers JR, 2093
Conkle D, 753
Connors TA, 1499
Cooney DA, 1095, 1137, 1291
Corbett TH, 799, 1459
Corder MP, 219, 763
Cornelissen G, 1428
Cornwell GG III, 399
Cortés-Funes H, 903
Costa J, 255, 739
Costanzi JJ, 1933, 2126
Coupal JJ, 951
Cox JD, 1251
Cox RS, 691
Creagan ET, 1589, 2061, 2105
Creasman WT, 319, 2089
Creech RH, 7, 111, 297, 513
Cricca A, 805
Crooke ST, 225, 899, 1503, 1821, 1829, 2118
Cruze D, 1809
Cummings FJ, 1363, 1371
Cunningham T, 121
Currie VE, 73, 1245, 1423, 2047
Curry S, 307

Cuttner J, 197
Cvitkovic E, 1399, 1585, 2019, 2107
Cysyk RL, 775

D

Daehnfeldt JL, 171
Dalager NA, 597
Dantchev D, 875
Davies J, 1835
Davis FF, 1127
Davis HL, 809
Davis RD, 1475
Davis TE, 297, 809
Dean JC, 359
De Bellis R, 197
Debusscher L, 363
Decker DG, 241
Dedrick RL, 59, 1939
DeFuria MD, 899
Degos L, 889
Deisseroth A, 461
Dembo AJ, 249
Denine EP, 1389
den Otter W, 99
Deppe G, 395
Deprez-de Campeneere D, 861
DeSimone PA, 391, 951, 2015
De Sloover C, 807
Desser RK, 2049
Dew K, 1493
De Wasch G, 827
De Weger RA, 99
DeWys WD, 158, 1675, 1693
Di Fronzo G, 915
Dicke KA, 1257
Didolkar MS, 1739
Dietrich M, 643
Dietz B, 219
D'Incalci M, 1375
DiSaia PJ, 319
DiStefano A, 539, 789, 2053
Dixon R, 307
Do HMT, 1271
Doering EJ, 1383
Dombernowsky P, 543
Dombrowsky PL, 211
Doney KC, 369
Donohue JP, 1573
Dorick DM, 1889
Doroshow JH, 269, 855
Dorr RT, 211
Douglass HO, Jr, 1355
Douros J, 1137
Dowd PM, 151
Dragon LH, 131
Drelichman A, 149
Drewinko B, 373
Driever CW, 13
Duda EE, 1707
Dullens HFJ, 99
Dyment PG, 1397

E

Eagan RT, 1589, 1965, 2081, 2105, 2130
Earhart RH, 230
East DR, 2077
Eddy JL, 713
Edelson RL, 659, 675
Edgerton F, 29
Edmonson JH, 241, 2061, 2081
Edwards GS, 551
Edwards MS, 1419
Ehrlich CE, 281
Eilber FR, 2005
Einhorn LH, 281, 1573, 1659
Elbadawi A, 1347
El Dareer SM, 201
Elias L, 1413
Ellemann K, 171
Elliott TE, 763
Elmer GW, 1055
Engstrom PF, 111
Epstein EH, Jr, 623, 701
Ettinger DS, 131, 457, 519
Ettinger LJ, 1615
Evans JT, 1355
Everall JD, 151
Evers JA, 1379
Ewy GA, 1809
Eyre HJ, 1557

F

Fabian CJ, 1359, 1933
Fagundo R, 497
Faiman C, 1327
Falkson G, 7, 177, 297, 1303
Falkson HC, 177, 1303
Falletta JM, 497
Farber EM, 691
Farr H, 1533
Feola J, 1409
Feun LG, 149
Finklestein JZ, 1331
Fischmann AB, 565, 571, 591, 619, 713
Fisher R, 647, 1557, 1663
Fisher RI, 147, 269
Fleming TR, 241, 2061, 2105
Fletcher WS, 1989
Flexner JM, 2123
Florczyk AP, 1821
Flye MW, 753
Foley JF, 511, 2093
Folks T, 613

Fontana JA, 224
Fossieck BE, Jr, 163, 713
Fox RM, 1997, 2011
Fraile RJ, 1983
Franks CR, 228
Fraumeni JF, Jr, 597, 2043
Freeman AI, 1615
Frei E III, 919, 1929
Freireich EJ, 373, 507, 1843
Frick GA, 13
Friedman J, 85
Friedman MA, 343, 351, 493, 1885
Friedman MJ, 1809
Fritz RR, 1063
Fruet F, 805, 1427
Frytak S, 1589, 2081, 2105
Fu KK, 351
Fujita H, 223
Fujita T, 2111
Fuks ZY, 581, 625, 691, 701
Fuller AF, Jr, 235

G

Gad-el-Mawla N, 227, 1577
Gagliano R, 2126
Gailani S, 1265
Gale GR, 449, 781
Gall SA, 319
Gallagher CG, 827
Garcia Miralles MT, 909
Garnick MB, 919, 1681, 1929
Garvin AJ, 255
Gaynon P, 1621
Gazdar AF, 575, 587, 713
George S, 1383
Gerold F, 1533
Gershow J, 493
Gerulath A, 289
Getaz EP, 2009
Gibson WR, 35
Gilchrest BA, 663
Giles HD, 1389
Ginsberg SJ, 1347
Giovanella BC, 945
Giovanna Tosana M, 1877
Giraldi T, 93
Giuliani ER, 1701
Glait HM, 983
Glass A, 2119
Glassberg AB, 493
Glatstein E, 729, 1649
Glaubiger DL, 1033, 2043
Glick J, 7
Glode LM, 1081
Gluck-Kuyt I, 797
Golbey RB, 1343, 1399, 1585, 1593, 2019, 2107
Goldberg J, 1347
Goldie JH, 1727
Goldsmith MA, 558
Goldstein JC, 489
Golitz LE, 701
Golomb FM, 1989
Golub G, 2035
Gomez GA, 1385
Gonzalez-Vitale JC, 2115
Good RA, 1428
Goodnight JE, Jr, 2005
Goodwin W, 1993
Gormley P, 1539
Gosálvez M, 903
Gota C, 2119
Gottlieb AJ, 1347
Gottlieb JA, 939
Gottlieb R, 307
Gouyette A, 1335
Gracia Marco M, 909
Grage TB, 1989
Gralla RJ, 17, 139, 549, 1007, 1343, 1399, 1585, 2097, 2107
Greco FA, 2015
Green AA, 547
Green L, 1271
Green M, 197
Green SB, 701
Greenberg L, 1621
Greenberg ML, 1953
Greenberg MS, 806
Greene HL, 1081
Greene MH, 597, 2043
Greenfield RS, 1089
Greenspan E, 297
Grekin DA, 623
Grever MR, 1949
Griem ML, 655, 1707
Griem SF, 655
Griffin TW, 1853
Griffing WJ, 35
Griffith K, 211
Griffith OW, 1115
Griffiths CT, 235, 275
Griswold DP, Jr, 799, 1459
Groppe CW, Jr, 795, 1557, 1663
Grose WE, 385
Grossman M, 675
Grotzinger KR, 269
Grozea PN, 647
Grubbs B, 477
Grundsell H, 421
Guardo A, 983
Guarino AM, 59, 1475, 1485
Guccion JG, 565, 571, 591
Günther U, 501
Gutterman JU, 1781

H

Haas CD, 1993
Haas RJ, 377

Haggard ME, 1383
Hahn GM, 1279
Hahn RG, 513, 1675
Halberg F, 1428
Hall SW, 85, 555
Halpin JJ, 1735
Hammond D, 977, 1331, 1621, 1755
Hamza R, 227, 1577
Hańka LJ, 1009, 1133
Hanlon K, 1707
Hansen HH, 485, 543
Hansen R, 1251
Hanson TA, 739
Hardy M, 675
Harrap KR, 1499
Harris DT, 111
Harrison SD, Jr, 1389
Harrold C, 1533
Harvey H, 307
Haskins CL, 647
Haus E, 1428
Haut A, 1359
Hayat M, 827, 875
Hayes FA, 547
Head GC, 739
Heim WJ, 1351
Heinz R, 827
Hekmatpanah J, 1707
Heller K, 1533
Henderson ES, 2009
Henderson IC, 919, 1929
Hendler FJ, 1707
Henry DW, 425, 845
Herman EH, 89, 1771
Herman TS, 359
Hersh EM, 115, 1781
Herson J, 155
Hewlett JS, 156, 525, 795
Higgins G, 1331
Hilaris BS, 1593
Hilgers RD, 301, 325
Hill DL, 201
Hill GJ II, 1989
Hill JM, 1509
Hill NO, 1509
Hillinger S, 489
Himmelstein KJ, 1515
Hincal AA, 229
Hodgson GS, 1761
Hoefer-Janker H, 501
Hoeschel JD, 951
Holcenberg JS, 1025, 1109
Holland JF, 558, 1013, 1265, 1599, 1953, 2039
Holtermann OA, 2009, 2071
Holyoke ED, 1739, 2009, 2031, 2071
Homesley H, 1549
Hoogstraten B, 1993
Hoovis ML, 1371
Hopfan S, 1593
Hoppe RT, 581, 625, 691
Horikoshi N, 931
Hortobagyi GN, 77, 115, 135, 539, 757, 1961, 2053
Horton J, 121, 297, 489
Hoshi A, 1895
Houchens DP, 473
Howard J, 1533
Howser D, 1539
Huff KK, 1271
Huftalen JB, 1503
Hundley RF, 2128
Hvizdala E, 1913, 2125
Hydes PC, 1503

I

Ihde DC, 163, 713, 1231
Iigo M, 1895
Imanishi J, 2111
Inagaki J, 931
Ingle JN, 1589, 1701, 2061, 2105
Inoue K, 931
Irequi M, 2009
Irwin LE, 797
Isacoff W, 643
Israel M, 919
Issell BF, 1821
Iwasaki M, 961
Izbicki RM, 999
Izquierdo JM, 909

J

Jackson AW, 1803
Jackson R, 1393
Jacobs EM, Jr, 1431
Jacobson N, 2099
Jacquillat Cl, 889
Jaffrey IS, 1953
Jaski JW, 489
Javadpour N, 1637, 1643, 1687
Jayaram HN, 1095, 1291
Jefferies JA, 241
Jegasothy B, 619
Johnson RK, 425, 473, 1291, 1857
Johnson WC, 681
Johnsson J-E, 421
Johnston-Early A, 163
Jolivet J, 1839
Jones SE, 647, 1605, 1809
Jorgensen EO, 241
Joseph U, 1993
Jungi WF, 1599

K

Kabakow B, 2101
Kalaher K, 1493

Kane R, 307
Kanter PM, 821
Kaplan BH, 311, 1005, 2039
Kaplan HG, 1363
Kaplan ME, 441
Karakousis CP, 1405, 1739, 2009, 2071
Kardinal CG, 215
Kariya S, 1291
Kaufman DA, 493
Keating MJ, 925, 939
Kelman AD, 1445
Kelsen DP, 2019, 2023, 2107
Kemeny NE, 139, 2097
Kempin S, 1423
Kennedy BJ, 215
Kessel DH, 899
Kessinger A, 511
Kessler A, 1787
Khaliq A, 53
Khan A, 1509
Khandekar JD, 1241
Khankhanian N, 411
Khouri NF, 519
Kimball JC, 552, 803
King FG, 1939
King GB, 1347
King GW, 1735
King JJ, 1509
Kinney YE, 775
Kishida T, 2111
Klaassen DJ, 289
Klahr C, 1, 141
Klastersky J, 363
Klein HO, 501
Klein J, 131
Kleinmann R, 1393
Klubes P, 1901
Knapp RC, 275
Knight EW, 121
Knight J, 1829
Knight WA III, 1933
Knutsen T, 575
Kobayashi T, 945
Kohn KW, 1439
Kolaric K, 827
Koller CA, 1949
Komaki R, 1251
Komp DM, 1397, 2125
Könyves I, 421
Kormano M, 2121
Kostinas JE, 197
Kovach JS, 1909, 1965
Kozak D, 1279
Koziol D, 123
Kozloff MF, 2049
Kraemer KG, 369
Krakoff IH, 73, 1245, 1523
Kramer WG, 13, 1821
Krauss S, 391
Kreis W, 1069
Krementz ET, 1989
Krivit W, 977, 1331, 1621, 1755
Krop S, 89
Kuentzel SL, 1971
Kukrika M, 307
Kumar PP, 713
Kuretani K, 1895
Kusunoki T, 2111
Kvols LK, 241, 1589, 1701, 2081, 2105
Kyle RA, 1265

L

Lacave AJ, 909
Lachenbruch PA, 763
Lagakos S, 121
LaGasse L, 1549
Lake-Lewin D, 1403
Lamberg SI, 561, 597, 619, 701, 725
Land VJ, 1383, 1397
Lane M, 551, 2027
Lassiani L, 93
Laster WR, Jr, 1311, 1459
Latreille J, 2001
Lau E, 377
Lau ME, 485
Lavin PT, 1355, 1863, 2031
Lazarus H, 1073
Lee BJ, 1403
Lee RE, 2130
Lee SS, 945
Lee WW, 425
Lee YJ, 1713, 1721
Legault-Poisson S, 1839
Legha SS, 115, 135, 539, 925, 1961, 2001, 2053
Leimert JT, 763
Lemoine R, 1335
Lemon HM, 511
Lenaz GR, 827
Lenhard RE, Jr, 519
Leone LA, 197
Lessner HF, 2015
Letendre L, 2081
Levin VA, 1419
Levine AS, 739, 753
Levitt M, 289, 1327
Lewis BJ, 341
LePage GA, 53
LeRoy AF, 59, 231, 1485
Li FP, 1929
Libnoch JA, 1251
Liepman M, 2115
Linden C, 1055
Lippman ME, 1143, 1271
Lipton A, 307
Lister TA, 127, 1853
Litterst CL, 59, 1475, 1485
Livingston RB, 939, 1933
Locker GY, 269, 855
Loeb E, 1509

Lohner D, 363
Lokys L, 1493
Long DF, 229
Loo TL, 85, 373, 415
Lopez R, 1739
Lorincz AL, 701
Love NH, 2077
Lovett J, 219
Lowenbraun S, 391
Luce JK, 529
Lukens JN, 2128
Lundbeck F, 183
Lutz RJ, 59

M

Mackey RW, 1245
Magno M, 1039
Magrini U, 1877
Maguire LC, 763
Makuch R, 163, 1539
Malkasian GD, 241
Maloney T, 1663
Malpas JS, 127
Malspeis L, 1949
Mañas A, 903
Mandel E, 395
Mangan C, 21
Mangioni C, 1375
Manning MR, 359
Manziuk LA, 827
Marabella PC, 29
Maral J, 889
Marmor JB, 1279
Maroun JA, 1781
Martimbeau PW, 301
Martinez L, 2009
Martini A, 915
Martini N, 1593
Martoni A, 1427
Maruyama Y, 1409
Mathé G, 875
Matthews MJ, 163, 565, 571, 575, 591, 713
Mattsson W, 171, 421, 827
Mavligit GM, 555
Mayer RJ, 1929
Mayhew E, 1923
Mayr AC, 827
McCoy JR, 1127
McCredie KB, 925, 939, 1257, 2001
McElwain TJ, 127
McGovren JP, 1971
McIntyre OR, 399, 1265
McKelvey EM, 647
McKeown J, 391
McMahon LJ, 359
McMillan C, 1913
Mead GD, 2043
Meadows GG, 1055
Meischen SJ, 449
Meister A, 1115
Mejias E, 1949
Meltz ML, 1795
Mendiola C, 903
Merrill JM, 158
Merrin CE, 1579
Metter GE, 1989
Metz EN, 1949
Meyer JA, 1347
Meyler FL, 869
Miale T, 1913
Michel B, 701
Miller AB, 289
Miller CF, 1351
Miller DS, 1475
Miller HG, 1901
Miller TJ, 1475
Mills PV, 1833
Minna JD, 163, 571, 575, 591, 713, 729
Mitchell BS, 1949
Mitrenga D, 501
Mittelman A, 1355
Mladineo J, 137
Moccio DM, 1889
Moertel CG, 1863, 1909, 1965
Moon TE, 301, 325, 1809
Moore D, 1993
Moore EC, 85
Moore MR, 2077
Moore R, 1739
Morgan J, 281
Morgan SK, 1383
Morrin B, 137
Mortel R, 307
Mortensen L, 1787
Morton DL, 226, 2005
Morton DM, 35
Moseley HS, 2005
Moss SE, 1989
Moukhtar M, 311, 1005
Mouridsen HT, 171
Moyano A, 903
Muggia FM, 7, 807, 1033, 1137, 1431, 1527, 1713, 1721, 1857, 1917
Mullen JL, 2099
Mulligan B, 1707
Munson D, 571
Murphy WK, 789, 1843, 1849
Myers CE, 147, 269, 855
Myers J, 1403

N

Nagura E, 931
Nakamura A, 1895
Neely CL, 209
Neil GL, 473, 1971
Nelson W, 1428

Netzel B, 377
Ninomiya K, 961
Nisce LZ, 633
Nisi C, 93
Nissen NI, 485, 1599
Nitschke R, 497, 1383, 1611
Nogeire C, 1953
Nystrom JS, 2035

O

O'Brien P, 1913
O'Connell MJ, 1909
O'Fallon JR, 1701
Ogawa G, 2117
Ogawa M, 931
Ohnuma T, 558, 1013, 1953
Oishi N, 149, 325
Oken MM, 441
Oldham R, 1367
Olivari AJ, 983
Oliver KT, 1853
Olson HM, 2057
Olson JE, 489
Omura GA, 209
Opipari M, 1663
Order SE, 131
Ospina J, 2009
Oster MW, 1417
Ostrowski MJ, 1803
O'Toole R, 325
Ovejera AA, 473
Ozols RF, 255, 269

P

Pagano M, 297
Paintrand M, 875
Pajak TF, 197, 399, 1265
Paladine W, 489
Palczuk NC, 1127
Palshof T, 171
Panettiere F, 1609
Pannuti F, 805, 1427
Panther SK, 763
Papahadjopoulos D, 1923
Pardue A, 1509
Parker LM, 235, 275, 1929
Parker N, 1781
Paroly WS, 1979
Partington J, 123
Parvinen M, 2121
Paterson AHG, 2124
Patt YZ, 555
Patterson RH, 565
Patton TF, 1515
Pearson JG, 289
Peck GL, 619
Peckham MJ, 1653
Pedersen H, 485
Peresie HJ, 1445
Perevodchikova NI, 827
Perez C, 405
Perez Llanderal JA, 909
Perloff M, 2039
Perry MC, 215
Petras V, 655
Petty W, 2089
Phillips TL, 351, 1885
Pinedo HM, 869
Pischer TL, 1419
Piver MS, 265
Plager C, 2027
Plunkett W, 415
Poisson R, 1839
Pollini C, 827
Polomano R, 2099
Portugal MA, 177, 1303
Powles RL, 127
Pradier R, 983
Praga C, 827
Pratt CB, 547
Preisler H, 2009
Prentice HG, 127
Presant CA, 1, 141, 1367
Prestayko AW, 1503, 1829, 2118
Prévost JM, 363
Price NM, 691
Pringle JF, 249
Pritchard JB, 1475
Pritchard JD, 555
Pugh RP, 1979
Pullen J, 1913

Q

Quesada JR, 1781

R

Raab SO, 1413
Raafat J, 675
Rabin H, 123
Radice PA, 1231
Ragab A, 155, 1913
Rahman A, 1787
Ramirez G, 1989
Randolph V, 1533
Raphael BG, 1343
Rappaport HW, 719
Rasmussen S, 1359
Ratkin GA, 1
Ravry MJR, 555
Reddick RL, 1527
Reich SD, 158, 225, 899

Reichert CM, 1527
Reinders E, 219
Repta AJ, 229, 1515
Resser KJ, 493, 1885
Reynolds TF, 1399
Rhie F, 121
Ribas A, 909
Ribaud P, 827
Ricci J, 307
Richie JP, 1681
Richman S, 1781
Ring BJ, 1025
Rivkin S, 301, 1663
Rizzo D, 29
Roberts J, 1045, 1123
Rodriguez Llorian AC, 909
Rodriguez V, 939
Roenigk HH, Jr, 669, 701, 729
Rogers W, 477
Rohruber W, 377
Romsdahl MM, 405
Rose C, 171
Rose WC, 1311, 1503
Rosenbaum C, 121
Rosenbaum EH, 493
Rosenberg B, 1433
Rosenberg C, 1393
Rosenberg SA, 739, 753
Rosenfeld HJ, 1045
Rosenthal DS, 1853
Ross DA, 781
Rossi AP, 805
Rossof AH, 1557, 1605, 1609
Rozencweig M, 807, 1431, 1527, 1713, 1917
Rubin J, 1701
Ruckdeschel JC, 489
Rudolph R, 529
Russell EK, 587
Rustum YM, 1923
Rybak ME, 1853

S

Sadée W, 343
Safai B, 633
Sakurai T, 223
Samson MK, 553, 1557, 1609, 1663, 1983, 2027
Sarna G, 2005
Sava G, 93
Sawada T, 2111
Schabel FM, Jr, 799, 1311, 1459
Schaison G, 889
Schechter GP, 565, 571, 575, 587, 713
Scheef W, 501
Schein PS, 1787
Scheving LE, 1428
Schiavone J, 395
Schilsky R, 1527, 1687
Schimpff SC, 2115
Schmer G, 1123
Schmid FA, 1045
Schmidt HJ, 319
Schnitker J, 501
Schoeman HS, 1303
Schreiner GE, 1787
Schuller DE, 1735
Schurig JE, 1503, 1821
Schutt AJ, 1909, 1965
Schwartz HS, 821
Schwartz P, 449
Schwarz MA, 1781
Seager ML, 1419
Seibert K, 2035
Seipp CA, 739, 753
Sekido S, 961
Seligman BR, 1265
Senn HJ, 827, 1669
Senzer N, 547
Sexauer CL, 155, 1397, 2125
Sgagias M, 131
Shackney SE, 163, 659
Shah J, 1533
Shannon CF, 2057
Shapiro CM, 2049
Sharma RN, 1327
Shaw MT, 1413
Sheid B, 43
Shen R-s, 1063
Shepard TH, 369
Sheridan MA, 473
Shingleton H, 1549
Sierocki JS, 1593
Silberman H, 209
Silver HKB, 226
Silverberg IJ, 351
Silvers SA, 489
Simon RM, 255, 739, 753, 1271, 1713, 1721
Singhakowinta A, 149
Sirotnak FM, 1889
Sivak M, 1953
Skarin AT, 1929
Sklaroff RB, 793, 2063
Slavik M, 1041
Slayton RE, 137, 297, 1675, 2089
Slioussartchouk V, 875
Smalley RV, 2077
Smiledge P, 2035
Smith AH, 613
Smith F, 1359
Smith FE, 551
Smith RE, 1735
Soehnlen F, 571
Sokal G, 895
Sokal JE, 1385
Solomon A, 391
Sonntag RW, 1599, 1669
Sonoda T, 391
Sorace RA, 43
Sörenson S, 543
Souhami RL, 1835

Spiers ASD, 1019
Spigelman MK, 395
Spiro R, 1533
Spittle MF, 639
Spitzer G, 1257
Stafford CT, 150
Staquet MJ, 1713, 1721, 1917
Stark JJ, 1681
Starling KA, 155, 1383, 1397, 1611
Stehlin JS, Jr, 945
Stein RS, 2123
Stephens RL, 325, 1359, 1557, 1609, 1663
Sternson LA, 1515
Stevens K, 177
Stevenson KE, 1745
Stewart DJ, 415
Stewart J, 1997
Stoller RG, 1363
Straus D, 793
Straus MJ, 767
Strong E, 1533
Strong JE, 1821, 1829
Strong JM, 775
Strøyer Christophersen I, 183
Stuckey WJ, 156
Sturgeon JFG, 249
Subramarian S, 1545
Sullivan MP, 155
Sutow WW, 405
Suzuki M, 529
Suzuki Y, 558
Sweet DL, 1707
Swenerton KD, 925, 1379
Szoka F, 1923

T

Tagnon HJ, 807
Takats L, 2124
Takita H, 29
Talley RW, 1557, 1605, 1983
Tan CTC, 17, 73, 1245
Tashima CK, 77, 115, 757
Tattersall MHN, 1997, 2011
Tavel AF, 1821
Taylor SG IV, 121, 158
Tejada F, 143
Ten Bokkel-Huyninck W, 827
Tennant J, 121
Thigpen JT, 21, 325, 525, 553, 1549, 1557
Thomas RJ, 701
Thompson EB, 189, 1271
Thomsen K, 709
Tillery KF, 201
Tilstone WJ, 1787
Tobelem G, 889
Todd GC, 35
Tokars RP, 655
Tornyos K, 391
Toyoshima S, 223
Trader MW, 1459
Tranum B, 1359
Trask C, 1835
Trevithick J, 1901
Trinca CE, 211
Tropé C, 421
Trouet A, 861, 895
Troyer C, 675
Trueworthy R, 2125
Trump DL, 457
Turell R, 395

U

Uchiyama T, 607
Ueoka H, 931
Ungaro P, 1367
Urbanek MA, 1475
Uren JR, 1073
Urtasun RC, 123

V

Vagenakis AG, 1393
Vaitkevicius VK, 149
Valdivieso M, 411, 939, 1843, 1849
Valencic M, 2101
Vallejo A, 1533
Van Amburg AL III, 141
van der Watt JJ, 1303
van Es T, 1127
van Eys J, 155, 1611
Van Scott EJ, 681, 701
Variakojis D, 655
Vélez-García E, 141
Venditti JM, 799
Vennegoor C, 99
Veras GH, 1311
Verma DS, 1257
Vietti TJ, 1611
Vigo PL, 827
Villa E, 827
Villani F, 915
Vinciguerra V, 197
Vistica DT, 1291
Vitale PJ, 457
Vogel CL, 2077
Vogel SJ, 1
Vogelzang NJ, 2067
Vogl SE, 311, 1005, 2039
Vogler WR, 209
Voigtmann R, 501
Volberding PA, 1885
Von Hoff DD, 807, 1033, 1527, 1539, 1917
Vonderheid EC, 681, 701
von Melchner H, 827
Vugrin D, 1399

W

Wade HE, 1019
Waldmann TA, 607
Waldner R, 827
Wallace S, 555
Wallach RC, 2101
Wallner PE, 681
Wampler G, 513
Wang A-Y, 757
Wang Y-M, 405
Waravdekar V, 89
Warrell RP, Jr, 1423
Warren R, 1271
Wasserman TH, 1885
Webb MJ, 241
Webber BL, 1629
Weil M, 889
Weiner JM, 1979, 2119
Weiss RB, 215
Wellner D, 1089
Weltz MD, 1351
Whang-Peng J, 575
Whisnant JK, 319
White D, 307
White GW, 1379
White LA, Jr, 215
Whitehouse JMA, 1745
Wick MM, 991
Wiesenfeld M, 219
Wilbanks G, Jr, 137
Williams CJ, 1745
Williams JE, 493
Williams SD, 281, 1573
Williams T, 1383
Wilson CB, 1419
Wilson HE, 156, 325
Wilson JF, 1251
Wiltshaw E, 1545
Winchester JF, 1787
Winters DW, 1795
Wiseman CL, 2053
Wittes RE, 1533, 1593, 2047
Wolberg WH, 1817
Wollman RL, 1707
Wolpert MK, 799
Wolpert-DeFilippes MK, 1453
Wolter J, 513
Wong PP, 1245
Woodcock T, 73
Woodruff R, 1853
Woods RL, 1997, 2011
Woolley PV III, 1039
Woutersen F, 99
Woutersen RA, 99
Wrigley PFM, 2085
Wu AT, 343

Y

Yagoda A, 1007, 1565
Yancey RS, 951
Yankee RA, 275
Yap B-S, 757, 1849
Yap H-Y, 77, 115, 757, 789, 2053
Yoo T-J, 219
Young CW, 17, 73, 255, 269, 333, 739, 793, 1245, 1343, 1399, 1403, 1423, 1527, 1539, 1687, 2023, 2063
Young RSK, 1771
Young SW, 581
Yuhas JM, 971

Z

Zackheim HS, 619, 623
Zaharko DS, 945
Zalusky R, 2101
Zamcheck N, 2031
Zamkoff K, 1347
Zander A, 1257
Zee-Cheng RK-Y, 425
Ziegler JL, 227, 1577
Zimmerman ANE, 869
Zubrod CG, 143
Zweig JI, 2101
Zwelling LA, 1439

Reviewers

We wish to thank the following Reviewers who participated in evaluating the manuscripts submitted to *Cancer Treatment Reports* during the past year:

Creed W. Abell
Martin D. Abeloff
Herbert Abelson
Ross Abrams
Edward M. Acton
Ian Adamson
Richard H. Adamson
Ram P. Agarwal
Krishna C. Agrawal
David L. Ahmann
Yeon-Socng Ahn
Joseph Aisner
Jane B. Alavi
David S. Alberts
Mohamed S. Al-Ibrahim
Joseph C. Allegra
Muhyi Al-Sarraf
Tom Anderson
Karen H. Antman
Mark M. Applefeld
Bach Ardalan
William P. Argy
Claude D. Arnaud
Kenneth Artiss
Alan R. Baker
Laurence H. Baker
Marie T. Bakowski
Jeffrey Baron
Sam C. Barranco
Robert C. Bast
Madeline A. P. Bauer
Edward S. Baum
Carlos Bekerman
Richard A. Bender
Robert S. Benjamin
John M. Bennett
R. Bensinger
John A. Benvenuto
Daniel E. Bergsagel
Thomas Berl
Joseph R. Bertino
Bijoy K. Bhuyan
David E. Bice
Margaret Billingham
Jacob D. Bitran
Ronald G. Blasberg
Werner A. Bleyer
Jerome B. Block
H. Blomgren
Joseph R. Bloomer
Ronald H. Blum
George R. Blumenschein
Gerald P. Bodey, Jr.
Arthur E. Bogden
Gianni Bonadonna
Vincent H. Bono, Jr.
Philip D. Bonomi
Edward C. Bradley
William T. Bradner
Luther W. Brady, Jr.
Paul G. Braunschweiger
Michael J. Brennan
Dean E. Brenner
Robert W. Brockman
Lawrence E. Broder
Richard H. Bromer
J. Martin Brown
W. R. Bruce
Howard W. Bruckner
C. Dean Buckner
Joan M. Bull
Joseph H. Burchenal
Philip J. Burke
Aman U. Buzdar
John E. Byfield
Fernando Cabanillas
Ed Cadman
Thomas P. Cameron
George P. Canellos
Robert Capizzi
Paul P. Carbone
Robert W. Carey
Desmond N. Carney
Ugo Carpentieri
Stephen K. Carter
Jane Cassidy
Franco Cavalli
Marjory Chadwick
A. Philippe Chahinian
Kenneth K. Chan
Paul Chang
Samuel Charache
Lloyd M. Charles, Jr.
Ram K. Chillar
Michael A. Chirigos
James H. Clark
Bayard Clarkson
Jacob J. Clement
Reginald A. Clift
William R. Cobb
Jordan L. Cohen
Martin H. Cohen
Philip Cohen
C. Norman Coleman
Morton Coleman
Jerry M. Collins
Steven J. Collins
Charles A. Coltman, Jr.
Robert L. Comis
T. A. Connors
R. Coombes
David A. Cooney
Thomas H. Corbett
Michael Corder
Engracio P. Cortes
Mary E. Costanza
John J. Costanzi
Kenneth Cowan
Edward T. Creagan
William A. Creasey
Patrick J. Creaven
Richard H. Creech
Stanley T. Crooke
Thomas J. Cunningham
Richard L. Cysyk
Giulio J. D'Angio
John R. Daniels
J. Paul Davignon
Hugh L. Davis, Jr.
Jack H. Dean
Ronald C. DeConti
Robert L. Dedrick
Ralph A. DeFronzo
Albert B. Deisseroth
Gregorio Delgado
E. Paul Denine
Warren H. Dennis
William D. DeWys
Robert B. Diasio
Charles H. Diggs
Nicholas R. DiLuzio
Aydin Dindogru
James V. Dingell
Philip J. Disaia
Dennis O. Dixon
Robert L. Dixon
Isaac Djerassi
Per Dombernowsky
Milton H. Donaldson
Ross C. Donehower
James H. Doroshow
Benjamin Drewinko
John S. Driscoll
Tony Dritschilo
Thomas P. Duffy
John R. Durant
Brian G. M. Durie
Frederick E. Durr
John S. Dutcher
Richard W. Dyke
Robert T. Eagan
Robert H. Earhart
Merrill J. Egorin
Lawrence H. Einhorn
Elias G. Elias
Rose Ruth Ellison
Paul F. Engstrom
William Ensminger
Charles Erlichman
Thomas J. Ervin
George C. Escher

Robert J. Esterhay, Jr.
David S. Ettinger
Audrey E. Evans
Lloyd K. Everson
Richard B. Everson
Carol Fabian
Stefan S. Fajans
Geoffrey Falkson
David Farquhar
Anthony S. Fauci
Alexander Fefer
Bernard Fisher
Richard I. Fisher
Jeffrey S. Flier
Clarence L. Fortner
Roberto J. Fraile
Arnold I. Freeman
Emil Frei III
Michael A. Friedman
Stephen Frytak
Karen Fu
Ruth A. Fugmann
Raymond L. Furner
Mitchell H. Gail
Glen R. Gale
Robert P. Gale
David Gee
Timothy S. Gee
Frank B. Gelder
Jack Geller
Ruth I. Geran
Beppino C. Giovanella
Andrew Glass
Daniel L. Glaubiger
Robert I. Glazer
John H. Glick
Robert B. Golbey
David W. Golde
John M. Goldman
Michael A. Goldsmith
Harvey M. Golomb
Sidney H. Golub
Robert Goodman
James E. Goodnight, Jr.
Paul E. Gormley
John S. Gottdiener
Arlan J. Gottlieb
Richard J. Gralla
Theodore E. Gram
F. Anthony Greco
Mark R. Green
Ezra M. Greenspan
Melvin L. Griem
John Griffin
Gerald B. Grindey
Daniel P. Griswold, Jr.
DuPont Guerry IV
Philip Gutin
Jordan U. Gutterman
Charles D. Haas
Davis M. Hahn
Mario Hakala
Daniel G. Haller
Anne Hamberger
Heine H. Hansen
Harold C. Harder
K. R. Harrap
John Harrington
David T. Harris
Steadman D. Harrison, Jr.
Charles M. Haskell
F. Ann Hayes
Charles Heidelberger
K. Hellmann
Edward S. Henderson
Fred J. Hendler
Jane E. Henney
Ronald B. Herberman
Eugene H. Herman
Evan Hersh
Geoffrey P. Herzig
Jeane Hester
J. C. Heuson
Donald J. Higby
Donald L. Hill
Richard I. Hill
Raymond N. Hiramoto
Dah Hsi Wang Ho
James F. Holland
Jimmie Holland
Ariel C. Hollinshead
E. Carmack Holmes
Paul Y. Holoye
Elton R. Homan
Barth Hoogstraten
Richard T. Hoppe
John Horton
Kathryn B. Horwitz
W. J. Hoskins
Daniel Hoth
David P. Houchens
Stephen B. Howell
Dianne M. Howser
Mark Huberman
G. Bennett Humphrey
Richard L. Humphrey
Dorris J. Hutchison
Frank Iber
James N. Ingle
William H. Isacoff
Brian F. Issell
Charlotte Jacobs
Samuel A. Jacobs
Robert J. Jacobson
Norman Jaffe
Nasser Javadpour
Michael Jensen-Akula
David G. Johns
Bonny L. Johnson
Randall K. Johnson
Gerald S. Johnston
Stephen E. Jones
R. L. Juliano
Herbert Kaizer
Muriel I. Kaiser-Kupfer
Richard S. Kaplan
Michael J. Keating
Diane E. Kelton
S. Kempin
B. J. Kennedy
Amanullah Khan
David T. Kiang
H. Kimelberg
Bruce F. Kimler
Daniel L. Kisner
Philip Klubes
Dankward Kodlin
Kurt W. Kohn
Diane M. Komp
Paul Kornblith
John S. Kovach
Irwin H. Krakoff
Barnett S. Kramer
Simon Kramer
Awtar Krishan
William Krivit
Thomas T. Kubota
Larry K. Kvols
M. Eugene Lahey
Stanford Lamberg
Montague Lane
W. R. Laster, Jr.
Ding-Jen Lee
Young Jack Lee
Sewa S. Legha
Steven A. Leibel
Gerald A. LePage
Howard E. Lessner
Harry H. LeVeen
Brigid G. Leventhal
John Levi
Victor A. Levin
Arthur S. Levine
Brian J. Lewis
Alan Lichter
Mortimer B. Lipsett
Allan Lipton
Robert H. Liss
Charles L. Litterst
Robert B. Livingston
Harris H. Lloyd
Albert F. LoBuglio
Gershon Y. Locker
Matthew S. Loewenstein
Jacob J. Lokich
Ti Li Loo
William B. Looney
D. Lynn Loriaux
Michael C. Lowe
Barry Lowitz
James K. Luce
W. B. Lundberg
Bernard Lytton
Ian I. Magrath
Andrea Manni
R. W. Manthei
Francis S. Markland
Charles Marks
Victor E. Marquez
Daniel S. Martin
Stephen J. Marx
Mary Matthews
Richard J. Mayer
Joseph E. Mayo
Denis M. McCarthy
Ernest S. McConnell
Kenneth B. McCredie
Timothy J. McElwain
J. Patrick McGovren
W. L. McGuire
William P. McGuire III
Eugene M. McKelvey
J. A. R. Mead
J. William Meakin

Daniel Medina
L. B. Mellett
Charles E. Mengel
Robert G. Mennel
Thomas C. Merigan
Claude E. Merrin
John S. Meyer
Raymond E. Meyn, Jr.
Frank L. Meyskins, Jr.
Denis R. Miller
Tony J. Miller
Rodney R. Million
Ming Yu Ming-Chu
John Minna
Malcolm Mitchell
Edward J. Modest
Charles G. Moertel
William C. Moloney
Eleanor Montague
Cora J. Morgan
Elaine Morgan
Lee Roy Morgan
Donald L. Morton
Franco M. Muggia
Gregory R. Mundy
John Munzenrider
Gerald P. Murphy
Sharon Murphy
Hyman B. Muss
Charles E. Myers
Benton M. Naff
Ven L. Narayanan
Larry Nathanson
James P. Neifeld
Gary L. Neil
Robert L. Nelson
Charles A. Nichol
Norman D. Nigro
Donald G. Norris
Larry Norton
Manuel Ochoa, Jr.
Michael J. O'Connell
Takao Ohnuma
Robert K. Oldham
George A. Omura
Stanley E. Order
C. Kent Osborne
Stanley Ostrow
Artemio A. Ovejera
Robert F. Ozols
Lawrence C. Panasci
Rose J. Papac
Leroy M. Parker
Robert E. Parks, Jr.
Kenneth Paull
Olaf H. Pearson
John C. Peckham
John S. Penta
Carlos A. Perez
David Perlman
Marjorie Perloff
Donald A. E. Peterson
Frederick S. Philips
T. M. Phillips
Theodore Phillips
Herbert Pinedo
C. M. Pinsky
M. Steven Piver
Philip A. Pizzo
Jacqueline Plowman
William Plunkett
Thomas C. Pomeroy
David G. Poplack
Carol D. Portlock
Jerome B. Posner
Donald S. Poster
Trevor J. Powles
Charles B. Pratt
Harvey D. Preisler
Cary A. Presant
Archie W. Prestayko
Richard W. Price
David J. Prieur
Marco Rabinovitz
Peter A. Radice
Abdel Ragab
Aquilur Rahman
Guillermo Ramirez
Joan Rankin
Howard Rasmussen
Victor Raso
Richard O. Recknagel
Carol K. Redmond
Donald J. Reed
Ronald R. Reimer
Steven D. Richman
Melvyn P. Richter
Helen Ridgway
Paul S. Ritch
Gaston Rivera
M. Maureen Roberts
Victorio Rodriguez
Howard Rogers
Mary A. Root
William C. Rose
Gerald Rosen
Charles Rosenbaum
M. Rosenblum
Fred Rosner
Arthur H. Rossof
Randall G. Rowland
Ivor Royston
Marcel Rozencweig
R. D. Rubens
John C. Ruckdeschel
Richard A. Rudders
Raymond W. Ruddon, Jr.
Thomas S. Ruh
Y. M. Rustum
Felix N. Rutledge
Wolfgang Sadée
B. Safai
S. Sallan
Sydney E. Salmon
Naguib A. Samaan
Michael K. Samson
Melvin L. Samuels
George W. Santos
Gregory Sarna
Alan C. Sartorelli
Priscilla P. Saunders
Frank M. Schabel, Jr.
Ulrich H. Schaeppi
Geraldine P. Schechter
Philip S. Schein
Charles A. Schiffer
Lewis M. Schiffer
Richard L. Schilsky
Lowell Schnipper
Allan J. Schutt
James Schwade
Allen D. Schwartz
Herbert S. Schwartz
Mary E. Sears
Albert Segaloff
Oleg S. Selawry
V. Sagar Sethi
Stanley E. Shackney
William R. Shapiro
Barry M. Sherman
Susan M. Sieber
Branimir Ivan Sikic
Richard M. Simon
Joseph V. Simone
Linda Simpson-Herren
A. Singhakowinta
Lucius F. Sinks
Francis M. Sirotnak
Andrew Sivak
Norman E. Sladek
Milan Slavik
Sherrill J. Slichter
Barbara Smith
Barry H. Smith
Frederick Smith
Mark Soloway
H. Dirk Sostman
James L. Speyer
Allen M. Spiegel
Robert J. Spiegel
Alexander S. D. Spiers
Gary Spitzer
Patricia Stott Stewart
Frank E. Stockdale
Robert L. Stolfi
Ronald Gary Stoller
Helen B. Stone
Marc J. Straus
James A. Straw
John M. Strong
Robert F. Struck
Robert K. Stuart
H. Tagnon
Martin H. N. Tattersall
D. Jane Taylor
Francisco Tejada
Joel Tepper
D. C. Thake
Tate Thigpen
Snorri S. Thorgeirsson
Douglass C. Tormey
Mary Trader
Lois Trench
Michael E. Trigg
Donald L. Trump
Richard S. Ungerleider
V. K. Vaitkevicius
Manuel Valdivieso
Frederick Valeriote
David Van Echo
Michael B. Van Scoy-Mosher
David T. Vistica
Paul J. Vitale
Charles L. Vogel

Steven E. Vogl
W. R. Vogler
Eric Vonderheid
Daniel Von Hoff
Davor Vugrin
James Wade
Michael D. Walker
Monroe E. Wall
H. James Wallace, Jr.
Patrick C. Walsh
Galen L. Wampler
Harold J. Wanebo
William Wara
Jerrold M. Ward
Todd H. Wasserman
L. H. Weiland
Roy S. Weiner
R. Weinkam
Howard Weinstein
John H. Weinstein
Larry M. Weisenthal
Arthur J. Weiss
William H. West
Moody Wharam
J. Taylor Wharton
Glynn P. Wheeler
Richard H. Wheeler
J. Courtland White
Lawrence W. Widerlite
Peter H. Wiernik
Albert L. Wiley, Jr.
Lee J. Wilkoff
James A. Will
Stephen D. Williams
James K. V. Willson, Jr.
Charles B. Wilson
Robert E. Wittes
Isidore Wodinsky
Kwang B. Woo
Thomas M. Woodcock
Peter W. Wright
Roy Wu
Alan Yagoda
Rosalyn Yalow
Boh-Seng Yap
Hwee-Yong Yap
Jerome W. Yates
David W. Yesair
Charles W. Young
David M. Young
Lowell S. Young
Robert C. Young
Norman Zamcheck
Gerhard Zbinden
Leonard A. Zwelling